

CLINICAL GUIDELINES

Arranged by system, and then alphabetical.

General	
Consultations	3
Guideline Guideline	4
Critical Care & Emergency Medicine	
Acute Coronary Syndrome (MI)	6
Cerebrovascular Accident	10
Death Protocol	13
Head Injury/Concussion (<18 years)	15
High-Flow Nasal Cannula (Pediatric)	16
Intubation (Adult and Pediatric)	17
Medevac Activation: Village to YKHC	20
Medevac Activation: YKHC to Anchorage	21
Military Transport for Emergencies	22
Pediatric Medevacs: Bethel to Anchorage	
Procedural Sedation & Analgesia Outside the OR	
Sepsis (Adult)	
Sepsis Medications (Adult)	
Sepsis (Pediatric)	
Status Epilepticus Treatment (Adult)	
Status Epilepticus Treatment (Pediatric)	
Pediatric Critical Care Weight-Based Guide:	
https://yk-health.org/wiki/File:Pediatric critical care guide.pdf	
Abuse/Assault	
Sexual Assault (≥18 Years)	ົ່
ocxual Assault (=10 Teals)	აა
Strangulation.	
	34
Strangulation	34 35
Strangulation Suspected Physical Abuse Procedure (Pediatric)	34 35
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric)	34 35 36
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI)	34 35 36 38
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular	34 35 36 38 42
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease	34 35 36 38 42 43
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease Congestive Heart Failure Hypertension	34 35 36 38 42 43
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease Congestive Heart Failure Hypertension Post-MI Management	34 35 36 38 42 43 45
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease Congestive Heart Failure Hypertension Post-MI Management Gastrointestinal, Hematologic, & Endocrine	34 35 36 38 42 43 45 46
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease Congestive Heart Failure Hypertension Post-MI Management Gastrointestinal, Hematologic, & Endocrine Diabetes, Type 2	34 35 36 38 42 43 45 46 48
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease Congestive Heart Failure Hypertension Post-MI Management Gastrointestinal, Hematologic, & Endocrine Diabetes, Type 2 Dyspepsia/H pylori (Adult and Pediatric) Iron Infusion for Chronic Iron-Deficiency Anemia (Adult and	34 35 36 38 42 43 45 46 48 50
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease Congestive Heart Failure Hypertension Post-MI Management Gastrointestinal, Hematologic, & Endocrine Diabetes, Type 2 Dyspepsia/H pylori (Adult and Pediatric)	34 35 36 38 42 43 45 46 48 50 51
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease Congestive Heart Failure Hypertension Post-MI Management Gastrointestinal, Hematologic, & Endocrine Diabetes, Type 2 Dyspepsia/H pylori (Adult and Pediatric) Iron Infusion for Chronic Iron-Deficiency Anemia (Adult and Pediatrics)	34 35 36 38 42 43 45 46 48 50 51
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease Congestive Heart Failure Hypertension Post-MI Management Gastrointestinal, Hematologic, & Endocrine Diabetes, Type 2 Dyspepsia/H pylori (Adult and Pediatric) Iron Infusion for Chronic Iron-Deficiency Anemia (Adult and Pediatrics) Osteoporosis Screening and Treatment	34 35 36 38 42 43 45 46 48 50 51 52
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease Congestive Heart Failure Hypertension Post-MI Management Gastrointestinal, Hematologic, & Endocrine Diabetes, Type 2 Dyspepsia/H pylori (Adult and Pediatric) Iron Infusion for Chronic Iron-Deficiency Anemia (Adult and Pediatrics) Osteoporosis Screening and Treatment Infectious Disease Amoxicillin Allergy Trials (Pediatric)	34 35 36 38 42 43 45 46 48 50 51 52 55
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease Congestive Heart Failure Hypertension Post-MI Management Gastrointestinal, Hematologic, & Endocrine Diabetes, Type 2 Dyspepsia/H pylori (Adult and Pediatric) Iron Infusion for Chronic Iron-Deficiency Anemia (Adult and Pediatrics) Osteoporosis Screening and Treatment Infectious Disease Amoxicillin Allergy Trials (Pediatric)	34 35 36 38 42 43 45 46 48 50 51 52 55 56
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease Congestive Heart Failure Hypertension Post-MI Management Gastrointestinal, Hematologic, & Endocrine Diabetes, Type 2 Dyspepsia/H pylori (Adult and Pediatric) Iron Infusion for Chronic Iron-Deficiency Anemia (Adult and Pediatrics) Osteoporosis Screening and Treatment Infectious Disease Amoxicillin Allergy Trials (Pediatric) Botulism Bronchiectasis/Chronic Cough (<18 years)	34 35 36 38 42 43 45 46 50 51 52 55 56 57
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease Congestive Heart Failure Hypertension Post-MI Management Gastrointestinal, Hematologic, & Endocrine Diabetes, Type 2 Dyspepsia/H pylori (Adult and Pediatric) Iron Infusion for Chronic Iron-Deficiency Anemia (Adult and Pediatrics) Osteoporosis Screening and Treatment Infectious Disease Amoxicillin Allergy Trials (Pediatric) Bronchiectasis/Chronic Cough (<18 years) Bronchiolitis/Wheezing (3-24 months)	34 35 36 38 42 43 45 46 50 51 52 55 56 57 58
Strangulation Suspected Physical Abuse Procedure (Pediatric) Suspected Sexual Abuse Procedure (Pediatric) Cardiovascular Acute Coronary Syndrome (MI) Aspirin for Adults >40 Without Known Cardiovascular Disease Congestive Heart Failure Hypertension Post-MI Management Gastrointestinal, Hematologic, & Endocrine Diabetes, Type 2 Dyspepsia/H pylori (Adult and Pediatric) Iron Infusion for Chronic Iron-Deficiency Anemia (Adult and Pediatrics) Osteoporosis Screening and Treatment Infectious Disease Amoxicillin Allergy Trials (Pediatric) Botulism Bronchiectasis/Chronic Cough (<18 years)	34 35 36 38 42 43 45 46 48 50 51 52 55 56 57 58 59

CLINICAL RESOURCE BOOK Table of Contents, page 1

nfectious Disease, continued

Influenza (Adult and Pediatric)	61
Lymphadenitis, Acute Cervical (Pediatric)	62
Otitis Media, Acute (3 months - 12 years)	63
Peritonsillar Abscess (Adults and Pediatric)	64
Pharyngitis (Adults and Pediatric)	65
Pneumonia (Adult)	66
Pneumonia (>3 months)	67
Procalcitonin in Lower Respiratory Tract Infections (Adult)	68
Rabies	69
Sepsis (Adult)	70
Sepsis Medications (Adult)	
Sepsis/Septic Shock (Pediatric)	
Sexually Transmitted Infections	
Sinusitis (>4 years)	
Skin and Soft Tissue Infection (Adult and Pediatric)	
Tuberculosis, Active Pulmonary (≥14 years)	
Tuberculosis, Latent (≥14 years)	
Tuberculosis Evaluation and Treatment (<14 years)	
UTI (Adult)	
UTI (3 months – 5 years)	
Varicella, Suspected	
	04
Neonatal/Pediatric Growth & Development	
Failure to Thrive in Children <24 Months	
Late Preterm Infants, Care of	88
Newborn Early-Onset Sepsis/GBS	89
Neonatal Jaundice	90
Neonatal Jaundice Neonatal Glucose Screening	
Neonatal Glucose Screening Neonatal Resuscitation Summary	91 92
Neonatal Glucose Screening	91 92
Neonatal Glucose Screening Neonatal Resuscitation Summary	91 92
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar	91 92 <mark>y.pdf</mark>
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar Neurology	91 92 y.pdf
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar Neurology Cerebrovascular Accident	91 92 y.pdf 95 98
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years)	91 92 y.pdf 95 98 99
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric)	91 92 y.pdf 95 98 99 100
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal resuscitation summar Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult)	91 92 y.pdf 95 98 99 100
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar/ Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult) Obstetrics	91 92 y.pdf 95 98 99 100 101
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult) Obstetrics Anemia in Pregnancy	91 92 y.pdf 95 98 99 99 100 101
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult) Obstetrics Anemia in Pregnancy Anti-D Immune Globulin	91 92 y.pdf 95 98 99 100 101 103 104
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult) Obstetrics Anemia in Pregnancy Anti-D Immune Globulin Diabetes, Gestational	91 92 y.pdf 95 98 99 100 101 103 104 105
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summary Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult) Obstetrics Anemia in Pregnancy Anti-D Immune Globulin Diabetes, Gestational Ectopic Pregnancy Treatment	91 92 y.pdf 95 98 99 100 101 103 104 105 106
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult) Obstetrics Anemia in Pregnancy Anti-D Immune Globulin Diabetes, Gestational Ectopic Pregnancy Treatment First Trimester Vaginal Bleeding	91 92 y.pdf 95 98 99 100 101 103 104 105 106 107
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult) Obstetrics Anemia in Pregnancy Anti-D Immune Globulin Diabetes, Gestational Ectopic Pregnancy Treatment First Trimester Vaginal Bleeding Group B Streptococcus (Matemal)	91 92 y.pdf 95 98 99 100 101 104 105 106 107 110
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult) Obstetrics Anemia in Pregnancy Anti-D Immune Globulin Diabetes, Gestational Ectopic Pregnancy Treatment First Trimester Vaginal Bleeding Group B Streptococcus (Matemal) HIV Screening and Prenatal Care	91 92 y.pdf 95 98 99 100 101 103 104 105 106 107 110
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult) Obstetrics Anemia in Pregnancy Anti-D Immune Globulin Diabetes, Gestational Ectopic Pregnancy Treatment First Trimester Vaginal Bleeding Group B Streptococcus (Matemal) HIV Screening and Prenatal Care Hypertension in Pregnancy, Chronic	91 92 y.pdf 95 98 99 100 101 103 104 105 106 107 110 111
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult) Obstetrics Anemia in Pregnancy Anti-D Immune Globulin Diabetes, Gestational Ectopic Pregnancy Treatment First Trimester Vaginal Bleeding Group B Streptococcus (Matemal) HIV Screening and Prenatal Care Hypertension in Pregnancy, Chronic Hypertension, Gestational	91 92 y.pdf 95 98 99 100 101 105 106 107 110 111 112 113
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summar Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult) Obstetrics Anemia in Pregnancy Anti-D Immune Globulin Diabetes, Gestational Ectopic Pregnancy Treatment First Trimester Vaginal Bleeding Group B Streptococcus (Matemal) HIV Screening and Prenatal Care Hypertension in Pregnancy, Chronic Hypertension, Gestational	91 92 y.pdf 95 98 99 100 101 103 104 105 106 107 110 111 112 113 114
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summary Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult) Obstetrics Anemia in Pregnancy Anti-D Immune Globulin Diabetes, Gestational Ectopic Pregnancy Treatment First Trimester Vaginal Bleeding Group B Streptococcus (Matemal) HIV Screening and Prenatal Care Hypertension in Pregnancy, Chronic Hypertension, Gestational Hypertension in Pregnant and Postpartum Patients, Severe Induction of Labor	91 92 y.pdf 95 98 99 100 101 103 104 105 105 106 107 110 111 112 114 116
Neonatal Glucose Screening Neonatal Resuscitation Summary	91 92 y.pdf 95 98 99 100 101 103 104 105 106 107 110 117 114 116 117
Neonatal Glucose Screening Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_summary Neurology Cerebrovascular Accident Head Injury/Concussion (<18 years) Seizure Evaluation (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Pediatric) Status Epilepticus Treatment (Adult) Obstetrics Anemia in Pregnancy Anti-D Immune Globulin Diabetes, Gestational Ectopic Pregnancy Treatment First Trimester Vaginal Bleeding Group B Streptococcus (Matemal) HIV Screening and Prenatal Care Hypertension in Pregnancy, Chronic Hypertension, Gestational Hypertension in Pregnant and Postpartum Patients, Severe Induction of Labor	91 92 y.pdf 95 98 99 100 101 103 104 105 105 106 107 110 111 112 113 114 117 118



Obstetrics, continued

Molar Pregnancy	120
Oligohydramnios	121
Post-Dates Pregnancy	122
Preterm Labor: Screening and Prevention	123
Preterm Labor: Evaluation	124
Preterm Labor: Treatment	125
Preterm Premature Rupture of Membranes	126
Vaginal Birth after C-section	127
Preventative Health Care	
Amoxicillin Allergy Trials (Pediatric)	129
Aspirin for Adults >40 Without Known Cardiovascular Disease	130
Breast Cancer Screening	131
Lead Evaluation (Pediatric)	132
Primary Care for Ex-Premies – Checklist	133
Sports Clearance for Pediatric Patients with History of COVID-19	134

Sports Clearance for Pediatric Patients with History of COVID-19...... 134 Osteoporosis Screening and Treatment...... 135

Psychiatry

Alcohol Hangover/Withdrawal	138
Attention Deficit Hyperactivity Disorder (Pediatric)	139
Intoxicated Patient	140
Involuntary Psychiatric Admissions	141
Trauma/Injury/Ingestion	
Trauma/Injury/Ingestion Acetaminophen Overdose (Adult and Pediatric)	143
Acetaminophen Overdose (Adult and Pediatric)	144

PROTOCOLS, REFERENCES, & RESOURCES

Arranged by department.


Neonatal Reference	
Neopuff Set-Up Guide	
Pneumothorax Evacuation Protocol	152
Surfactant Administration Protocol	153
Village Deliveries	154
Obstetrics Protocols/Reference	
Antepartum Patient	
Prenatal Care	157
Outpatient Protocols/Reference	
Chronic Pain: Narcotic Treatment Eligibility	159
Chronic Pain, Follow-up	
Colon Cancer Screening	161
Contraception: Quick Start	162
Pre-anesthesia Testing	

CLINICAL RESOURCE BOOK Table of Contents, page 2

Pediatric Protocols/Reference

Caffeine Protocol, Post-NICU Discharge	166
Care Conference Checklist	167
Dexamethasone in Meningitis	168
Diabetic Ketoacidosis Management	169
Endocrine Emergencies	172
Endocrine Referrals/Labs and Follow-up Recommendations	175
Hip Exam and Surveillance in Infants	178
Induced Sputum Collection	179
mPEWS Protocol for Pediatric Patients	180
Nutritional Supplements, Documentation Requirements	181
Orthotics, Documentation Requirements	182
Suspected Septic Arthritis and Osteomyelitis	183

For COVID Guidelines, click here.





Clinical Guideline Guideline Guideline

Miscellaneous


• Guidelines are to be reviewed every two years with revisions and updates as appropriate. Updates may happen sooner as needed.

• The Guideline Coordinator will keep track of the guideline review schedule.

• Deadlines for feedback will generally be a period of two weeks.

• Lack of response by email is viewed as assent/lack of disagreement.

At any time, anyone may send feedback on a guideline to the point person named in the gray box at the bottom of the guideline or the Guideline Coordinator. This feedback will be saved for the next guideline revision.
Minor changes including (but not limited to) correction of typos, changes in test names, small additions, updating hyperlinks, and changes in contact information may be made and published without MSEC approval.



Wiki The long-term goal for the guidelines is for every guideline to have a corresponding supplemental page on the wiki. The guideline will be information needed to take care of a patient in the moment. The wiki supplement will include references, resources, historical background, past versions, and other information.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 9/2/20.

If comments about this guideline, please contact Leslie_Herrmann@ykhc.org






Critical Care & Emergency Medicine	
Acute Coronary Syndrome (MI)	.6
Cerebrovascular Accident	.10
Death Protocol	.13
Head Injury/Concussion (<18 years)	. 15
High-Flow Nasal Cannula (Pediatric)	. 16
Intubation (Adult and Pediatric)	.17
Medevac Activation: Village to YKHC	. 20
Medevac Activation: YKHC to Anchorage	21
Military Transport for Emergencies	. 22
Pediatric Medevacs: Bethel to Anchorage	. 23
Procedural Sedation & Analgesia Outside the OR	.24
Sepsis (Adult)	.26
Sepsis Medications (Adult)	.27
Sepsis (Pediatric)	. 29
Status Epilepticus Treatment (Adult)	30
Status Epilepticus Treatment (Pediatric)	31
Pediatric Critical Care Weight-Based Guide: https://yk-health.org/wiki/File:Pediatric_critical_care_guide.pdf	



Yukon-Kuskokwim

Clinical Guideline

Acute Coronary Syndrome (ACS) Management





Yukon-Kuskokwim HEALTH CORPORATION

Clinical Guideline

Acute Coronary Syndrome (ACS) Management

Nitroglycerin (NIG)
 Contraindications:
PDE-inhibitor use,
cardiogenic shock, RV
infarct, sBP<90,
marked tachycardia or
bradycardia.
 Sublingual dosing:
0.4 mg SL Q5 minutes
up to three doses
 <u>IV dosing</u>: start at
10-20 mcg/min, titrate
Q3-4 minutes to
typical range 60-100
mcg/min

Beta-Blockers • No evidence of benefit from routine immediate betablocker.

 Indicated for HTN and/or ongoing ischemia refractory to NTG.
 <u>Contraindications</u>: cardiogenic shock, RV

infarct, symptomatic asthma. • <u>Cautions</u>: risk for cardiogenic shock

(bradycardia, HR>110, sBP<120, age>70, increased time since STEMI onset), inferior MI, controlled asthma.

	Emergency Department Medication Summary				
		STEMI <12 hours	STEMI >12 hours	NSTE-ACS	
	Oxygen	Maintain SpO ₂ 90-96%	Maintain SpO ₂ 90-96%	Maintain SpO ₂ 90-96%	At time
	Nitrates (<i>prn</i> pain, HTN)	Sublingual or drip	Sublingual or drip	Sublingual or drip	◀ ♀
	Fibrinolytic	Tenecteplase See page 1, Box 5	Not indicated	Not indicated	Dx unless
ß	Aspirin	325 mg PO (chewed)	325 mg PO (chewed)	325 mg PO (chewed)	
telet agents	P2Y ₁₂ receptor blocker	Clopidogrel Age ≤75: 300 mg PO Age >75: 75 mg PO	Clopidogrel 600 mg PO	Consult cardiology.	contraindicated
Antiplatelet	Glycoprotein IIb/IIIa inhibitor	Eptifibatide (Integrilin) Per cardiologist. Typically given after PCI.	Eptifibatide (Integrilin) Per cardiologist. Typically given after PCI.	Eptifibatide (Integrilin) Per cardiologist. Typically given after PCI.	ted
	Anticoagulation	Enoxaparin (see table for dose)	Enoxaparin (see table for dose)	Enoxaparin (see table for dose)	
	Beta-blocker	Metoprolol 5 mg IV <i>pm</i> Q5 minutes (max 15 mg)	Metoprolol 5 mg IV <i>pm</i> Q5 minutes (max 15 mg)	Metoprolol 5 mg IV <i>pm</i> Q5 minutes (max 15 mg)	
	Morphine	u u u u u u u u u u u u u u u u u u u	tinely given; associated with increa gnificant pain refractory to NTG an		

Enoxaparin Dosing		
Age <75 years and STEMI	Age ≥75 years and STEM	Any age and NSTE-ACS
30 mg IV + (1 mg/kg SC now then Q12h) Max dose 100 mg	0.75 mg/kg SC Q12h Max dose 75 mg	1 mg/kg SC now then Q12h
Creatinine clearance <30 mL/min 30 mg IV + (1 mg/kg SC now then Q24h) Max dose 100 mg		1 mg/kg SC now then Q24h
	30 mg IV + (1 mg/kg SC now then Q12h) Max dose 100 mg 30 mg IV + (1 mg/kg SC now then Q24h)	30 mg IV + (1 mg/kg SC now then Q12h) Max dose 100 mg0.75 mg/kg SC Q12h Max dose 75 mg30 mg IV + (1 mg/kg SC now then Q24h)1 mg/kg SC Q24h

which is not on the YKHC formulary. Discuss with cardiologist if appropriate.

Inpatient Medication Summary		
NOTE: The following table is meant to be a basic reference as a starting point. Please consult Cardiology for full recommendations in all ACS patients.		
ACE-inhibitor	Lisinopril 2.5 – 5 mg PO daily Give unless contraindicated. Typically started prior to hospital discharge. Unclear if ED initiation is beneficial.	
Statin	Atorvastatin 80 mg PO daily Give unless contraindicated. Typically started prior to hospital discharge. Unclear if ED initiation is beneficial.	
Beta-blocker	Metoprolol XL 25-50 mg PO Q12-24h <i>pm</i> Give unless contraindicated. Typically started prior to hospital discharge.	
Clopidogrel	75 mg PO daily	
Aspirin	81 mg PO daily	
Enoxaparin	Dose above. Consult Cardiology for duration.	

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 12/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Megan_Young@ykhc.org and Andrew_Swartz@ykhc.org.



Yukon-KuskokwimClinical GuidelineHEALTH CORPORATIONAcute Coronary Syndrome (ACS) Management

Fibrinolytic Checklist		
INDICATIONS (initial yes or no)		
YES	NO	
		Presentation consistent with acute coronary syndrome (coronary artery occlusion)
		AND at least one of the following: • 1 mm J-point elevation in two contiguous leads (other than V ₂ -V ₃) • In leads V2-V3 Men ≥ 40 years: ≥ 2 mm J-point elevation Men <40: ≥ 2.5 mm J-point elevation Women: ≥ 1.5 mm J-point elevation
ABSOLUTE	CONTRAINDICA	NTIONS (initial yes or no)
YES	NO	
		History of any intracranial hemorrhage
		History of prior ischemic stroke, significant closed head injury or facial trauma, or intracranial or spinal surgery in the previous three months
		Presence of a cerebral vascular malformation
		Presence of a primary or metastatic intracranial malignancy
		Symptoms or signs suggestive of an aortic dissection
		Any bleeding diathesis
		Any active bleeding that is severe or has high potential for life-threatening blood loss; this does not include menstrual bleeding
		sBP > 180 and/or dBP >110 at presentation in patient at low risk of cardiac death (age < 55, no prior MI, and Killip class I).
		Terminal illness, defined as end of life care or documented/expressed patient wish to abstain from high risk or invasive procedures
RELATIVE C	ONTRAINDICAT	FIONS (initial yes or no) – If any of below are present, used shared decision making with patient.
YES	NO	
		Age 65-74 (ICH relative risk 3.12 [2.54-3.83]); Age ≥ 75 years (ICH relative risk 5.40 [4.40-6.63])
		History of chronic severe poorly controlled HTN
		sBP > 180 and/or dBP >110 at presentation in patient at high risk of cardiac death (age \ge 55, Hx prior MI, or <u>Killip class \ge II).</u>
		History of ischemic stroke more than three months ago
		Dementia OR any known intracranial disease that is not an absolute contraindication
		Traumatic or prolonged (>10 minutes) cardiopulmonary resuscitation
		Major surgery in the previous three weeks
		Internal bleeding in the previous 2-4 weeks
		Active peptic ulcer
		Non-compressible vascular punctures
		Pregnancy
		Current warfarin therapy (the risk of bleeding increases as the INR increases)

This checklist is advisory for clinical decision-making and may not be all-inclusive. Risks and benefits will need to be assessed individually.

Physician signature: _

Printed name:


_ Date and time: _



Acute Coronary Syndrome (ACS) Management

PROCEDURE CONSENT	
I hereby authorize following operation or procedure	and such assistants as he/she may designate, to perform the
TECHNICAL DESCRIPTION	Intravenous thrombolytic therapy for acute STEMI (ST-elevation myocardial infarction).
LAY DESCRIPTION	Give clot-dissolving medication through an IV to dissolve the clot which is causing a heart attack.
	has discussed with me the information briefly summarized below:
BENEFITS	 When PCI is not available within two hours, thrombolytic medication is the "standard of care" for achieving coronary reperfusion within 12 hours of acute STEMI onset. When administered within 6 hours of pain onset, about 1 in 40 persons will have their life saved. When administered between 6-12 hours after pain onset, about 1 in 60 persons will have their life saved. Decreased risk of developing heart failure. A STEMI patient who receives thrombolytic medication is about 3-5 times more likely to have their life saved than to have brain bleeding (see below).
	 About 1 in 100 persons will experience non-life-threatening bleeding. About 1 in 100-250 persons will experience bleeding into the brain which usually results in either death or significant disability.
RISKS OF NOT HAVING THE PROCEDURE	 Higher risk of death. Higher risk of developing heart failure.
ALTERNATIVE TREATMENTS	None are available at this facility.

Patient signature:	Witness signature:
Printed name: Date and time:	Printed name: Date and time:
Physician signature:	Witness signature:
Printed name: Date and time:	Printed name: Date and time:





Thrombolytic Checklist

INDICATIONS (initial yes or no)				
YES	NO			
		Less than 4.5 hours since onset of symptoms or last known normal.		
		NIHSS greater than 5 (or less than 5 with disabling symptoms).		
		Symptoms are NOT rapidly improving.		
		Symptoms are NOT due to untreated hypoglycemia (BG<50).		

ABSOLUTE CONTRAINDICATIONS (initial yes or no)

YES	NO	
		CT evidence of hemorrhage OR extensive area of hypodensity (irreversible injury).
		GI/GU bleed in the last 21 days.
		Severe, uncontrolled, hypertension >185/110.
		Current intracranial neoplasm.
		Active internal bleeding or known aortic dissection.
		Any bleeding diathesis.
		Presentation suggestive of SAH or endocarditis (not septic emboli).
		History of intracranial hemorrhage.
		Anticoagulation (warfarin or DOAC in the last 48 hours or therapeutic-dosed heparinoids).
		Any of the following in the last three months: ischemic stroke, intracranial surgery, intraspinal surgery, or serious head trauma.

RELATIVE CONTRAINDICATIONS (initial yes or no) – If any of the following relative contraindications are present, consider expert consultation prior to giving thrombinolytic and/or consider these with consent and shared decision-making.

YES	NO	
		History of GI or GU hemorrhage.
		Arterial puncture in a non-compressible site in the last seven days.
		Seizure at onset with postictal neurologic impairment.
		Major surgery in the last 14 days.
		Pregnancy.
		Onset 3-4.5 hours with NIHSS >25 (higher bleeding risk) or age >80 (higher bleeding risk).
		Untreated AVM or aneurysm.
		Systemic malignancy.
		History of arterial dissections.
		Blood glucose greater than 400 (associated with worse outcomes).

This checklist is advisory for clinical decision-making and may not be all-inclusive. Risks and benefits will need to be assessed individually.

Physician signature: _

Printed name: _

____ Date and time: _



Cerebrovascular Accident

PROCEDURE CONSENT	-				
I hereby authorize following operation or procedure	:	and such assistants as he/she may designate, to perform the			
TECHNICAL DESCRIPTION	Intravenous thrombolytic therapy fo	or acute ischemic stroke.			
LAY DESCRIPTION	Give clot-dissolving medication thro	ough an IV to dissolve the clot which is causing a stroke.			
	$_$ has discussed with me the information briefly	/ summarized below:			
BENEFITS	 had a good outcome. In patients who did not help one person have a better outcome. If these drugs were given between three and drugs had a good outcome, and 30% of patie drug to help one person have a better outcom Patients who receive this drug within three h survival. 	an three hours after the stroke started, 33% of patients given thrombolytic drugs get thrombolytic drugs, 23% got better. Ten people would have to get the drug to ad four and a half hours after the stroke started, 35% of patients given thrombolytic ents who didn't get the drug also got better. Twenty people would have to get the			
	 In a large study of stroke patients, 6.8% of them had bleeding in their brain after receiving thrombolytic drugs for stroke, compared to 1.3% of those stroke patients who did not receive the drug. If we give this drug 18 times, it will probably make one person have bleeding in their brain. Among all people given this drug, 2% die from a hemorrhage. 				
RISKS OF NOT HAVING THE PROCEDURE	Higher risk of developing permanent, disabling stroke symptoms.				
ALTERNATIVE TREATMENTS	No other treatments available at this facility.	Only monitoring symptoms and rehabilitation.			
Patient signature:	Date and time:	Witness signature:			
[]			
Physician signature:		Witness signature:			
Printed name:	Date and time:	Printed name: Date and time:			



Patient with serious illness with expected death.

•

Preparation, as appropriate

- · Complete Medical Orders for the Scope of Treatment (MOST) order form. Review with patient and family regularly.
- Review DNR/DNI status at least once an admission.
- Place DNR/DNI order in RAVEN.
- \bullet Update code status on RAVEN banner by going to Ad hoc \rightarrow Code Status form.
- Remember, all decisions regarding end-of-life care may be modified at any time per patient and family wishes.
- Complete Expected Home Death form and send to AST/BPD.
- · Communicate with village health aides.
- Place on RAVEN banner by going to AdHoc \rightarrow Patient Registries and check off "Expected Home Death."

• When discharging home, ensure all support is in place, including family care plan, comfort meds (consider sublingual morphine and lorazepam), incontinence supplies, etc.

When death appears imminent

Communicate with nurses or health aides and family. Speaker phone and/or Vidyo are very helpful for village communication.
Be supportive of staff, especially health aides. Be as present as possible.

Caring for a dying patient is very stressful, especially for newer health aides; good communication can decrease some of the burden they feel.

After a home death has occurred

Medical providers can pronounce death remotely after speaking with a qualified representative, which includes health aides. Representative must ascertain that there is no heart beat or spontaneous breathing.
Send Expected Home Death form to the State Medical Examiner and AST/BPD. If this form was not completed prior to death but would have been indicated, it is acceptable to fill it out after death. This will expedite things for the family.

Contact CHAP on call to request support for health aides.

State Medical Examiner (888 332-3273) only if manner of death was unrelated to terminal illness and/or suspicious in any way.
Life Alaska (888 543-3287) if patient was <85 years. Obtain reference number.
AST(800 478-9112) if in village or BPD (543-3781). Even if an Expected Home Death form has been completed, law enforcement requests a phone call at the time of death.

Notifications

Documentation

• Death Note in RAVEN should be an Alert Note that includes: time of death, ME case number (if applicable), Life Alaska reference number, circumstances of death, and documentation that all required notifications have occurred. May use Free Text template and autotext "..death" for a fillable note.

Forward death note to Chief of Staff and designated Medical Records representative.
Complete the <u>Death Certificate Worksheet</u> for deaths that are not ME cases.
If death occurred in the hospital, complete <u>Notification of Death</u> form.

Helpful Phone Numbers

- Alaska State Medical Examiner: 888 332-3273
- Life Alaska: 907 562-5433
- Alaska State Troopers (AST): 800 478-9112
- Bethel Police Department (BPD): 543-3781

Helpful Forms

Note: Copies of the death packet are also kept on the inpatient unit.

Medical Orders for the Scope of Treatment (MOST)

Expected Home Death


Death Certificate Worksheet

Notification of Death

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 9/2/20. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.



Yukon-Kuskokwim



Helpful Forms

Note: Copies of the death packet are also kept in the ED and inpatient.


• Death Certificate Worksheet

• Notification of Death

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 9/2/20. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.



Head Injury in Patients < 18 Years Old





Clinical Guideline

High-Flow Nasal Cannula (Pediatric)

REMEMBER:

- No pediatric patient may be kept at YKDRH on
- HFNC unless medevac is on weather-hold.
- Maintain patient on HFNC until medevac arrival.
 Requirements for HFNC:
 - The patient must have 1:1 nursing care until he/she has stabilized. After stabilization, nursing care may be 2:1 until medevac arrival.
 - □ The patient must have a respiratory therapist at bedside until stabilized.

 Prior to starting HFNC, physicians, bedside nurses, charge nurses, and RT will huddle to determine which unit will care for the patient. This will be decided on a case-by-case basis. Considerations include:

- a How long is the patient expected to remain at YKDRH? Will that time exceed the time provided by an H-cylinder?
- How much risk will be added by moving the patient after stabilization on HFNC?
- Experience level of nurses who will care for the patient.

• All newborns on HFNC must remain in the nursery.

Flow Rates

Titrate flow to 0.5-2 LPM/kg. Younger patients often require higher flow rates per kilogram.

Consult the PICU for any patient requiring >1 LPM/kg.

Listen to lungs with each adjustment. If child is unable to easily exhale or complete an exhalation, decrease flow rate until exhalation is adequate.


Troubleshooting

Consider NG/OG-tube for decompression.
 Use a pacifier to keep the patient's mouth closed and prevent loss of pressure. Consider

Sweet-Ease. • Try environmental changes to comfort a fussy baby: caregiver may hold patient in semirecumbent position, patient may be swaddled, patient may be fanned if hot, lights may be dimmed, etc.

- Consider mild anxiolysis in consultation with medical control.
- Consider higher levels of flow to improve washout.

Patient with moderate to severe sustained retractions or sustained hypoxia <88% not improved with <u>SUPPORTIVE MEASURES</u> (see box) and 2 LPM conventional nasal cannula or infant with apnea responsive to stimulation



Maintain current settings until medevac arrives.

- SUPPORTIVE MEASURES
- Control fever, as it can be an independent cause of respiratory distress.
- Nasal suction.
- IV hydration.
- Consider back-to-back nebs with albuterol or normal saline.
- normal sain
 - Consider phenylephrine nasal spray to each nostril once.
 - Consider hypertonic saline nebs q6h.

PREPARE PATIENT


- Make patient NPO.
- Ensure reliable IV access.
- Suction nares well.
- Choose a nasal cannula with prongs that do not occlude more than 50% of the nares.

Position patient: optimal patient position is semirecumbent, not supine or upright. Consider using blue seat (stored in the ED) with adjustable angle. Use blanket rolls to support position and ensure patient is not slumping over. Caregivers may hold the child if it helps keep him/her calm as long as the child is at a ~45 degree angle.
To prevent condensation causing problems, place patient at a higher level than unit and clip tubing to patient's clothing.

NOTE:

Low-flow cartridge to be used with neonatal/ infant cannula and produces flow rates of 1-8 LPM. This should only be used in patients ≤ 4 kg.
High-flow cartridge to be used with larger cannula and produces flow rates of 5-40 LPM.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 4/14/20. Click here to see the supplemental resources for this guideline. If comments about this guide line, please contact Leslie_Herrmann@ykhc.org.



Consider C-collar.

If comments about this guideline, please contact Travis_Nelson@ykhc.org or Leslie_Herrmann@ykhc.org



Clinical Guideline

Intubation (Adult and Pediatrics)

Predictors of Difficult Intubation

Predictors of Difficult Intubation

- Mallampati grade 3 or 4
 Cormack & Lehane grade 3 or 4
- Wilson score of > 2
- · LEMON system; objective/subjective scoring

Wilso	n Score		
	0	1	2
Weight (kg)	< 90	90-110	> 110
Head and neck movement	> 90°	~ 90°	< 90°
 Inter-incisor gap (cm) SL (maximum forward protrusion of lower incisors beyond uppers) 	> 5 > 0	= 5 = 0	< 5 < 0
Receding mandible	None	Moderate	Severe
Buck teeth	None	Moderate	Severe

	LEMON System
L	Look: trauma, large tongue
Е	Evaluate 3:3:2 rule.
м	M allampati score ≥3
0	Obstruction
N	Neck mobility (limited)

Helpful Resource: the Difficult Airway App

Use of Succinylcholine

Absolute contraindications:


Family / personal history of malignant hyperthermia Hyperkalemia; if unknown K, obtain EKG for peaked T's Upper motor neuron injury, denerving neuromuscular disease Use after acute phase of burns, major trauma, crush injury

Relative contraindications:

Elevated ICP Pseudocholinesterace deficiency

Treatment of malignant hyperthermia:

Dantrolene 2.5 mg/kg IV, redosing based on expert guidance



Difficulty with BVM

Predictors of Difficulty with BVM

- R Radiation/Restriction
- 0 Obstruction/Obesity/OSA

Μ Mask seal/Male/Mallampati ≥3

Α Aged

Ν No teeth

Options if having difficulty with BVM

- 2-hand technique with 2 providers
- Oral/nasal airways Positioning
- Consider no paralytics

Resources: Guideline adapted from Strayer Airway Algorithm, Austin Hospital Airway Algorithm, Difficult Airway Course Predictors of Difficult Intubation: http://medind.nic.in/iad/t05/i4/iadt05i4p257.pdf

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC12/7/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Travis_Nelson@ykhc.org.



ADULTS: ARDS/Protective Ventilation Protocol (appropriate for most patients without indication for alternate ventilation)

Initial Ventilator Settings:

- (1) Set Tidal volume (Vt) = 6-8 mL/kg using Ideal Body Weight. See MDCalc Tidal Volume Calculator.
- (2) Reduce Vt by 1 mL/kg every 1-2 hours until Vt 6 mL/kg.
- (3) Set initial rate to 18-35 bpm based on pre-intubation rate.
- Obstructive lung disease: Consider lower RR to maximize expiratory phase.
- (4) Set initial PEEP at 5 cm H2O.
 - If BMI > 30, set PEEP to 8 cm H2O.
 - If BMI > 40, set PEEP to 10 cm H2O.
- (5) Set initial FiO2 at 30-40%; adjust to SpO2 88-95%.
- (6) Set inspiratory flow rate 60-80 lpm.

Obstructive lung disease: Consider inspiratory flow rate 80-100 lpm

Adjust settings based on patient status, blood gases, CXR, and expert consultation.

Oxygenation goal: PaO_2 55-80 mmHg or SpO₂ 88-95%. Use a minimum PEEP of 5 cm H₂O. Consider use of incremental FiO₂/PEEP combinations such as shown below (not required) to achieve goal.

PEDIATRICS: Suggested Starting Ventilator Settings

1. Set FiO₂ to 1.0 and titrate to maintain SpO₂ 92-94%. Goal is to decrease FiO₂ to <0.5 if possible.

- 2. Set Tidal Volume (Vt) at 8-10 mL/kg. If concern for ARDS, set Vt to 6-8 mL/kg.
- Goal is inspiratory plateau pressures <30 cm H₂O.
- 4. Set respiratory rate by age, increasing or decreasing based on disease process:
 - Adolescents 12-15 breaths/minute
 - Children 15-20 breaths/minute
 - Infants 20-25 breaths/minute
 - Neonates 25-30 breaths/minute
- 5. Set PEEP to 5 cm H₂O to optimize alveolar recruitment.
- 6. Set inspiratory time by age:
 - Adolescents 1.0 second
 - Children 0.7 second
 - Infants/neonates 0.5 second
- 7. If using pressure support, set at 5-10 cm H_2O .
- 8. Get a blood gas ~30 minutes after any changes to ventilator settings.

Call PICU at (907) 297-8809 immediately to help troubleshoot any problems.

For All Modes of Ventilation

• Initial vent setting are based on patient presentation.


 Vent settings are adjusted based on patient tolerance of mechanical ventilation and ABG results. For high PCO₂: increase rate and Tidal Volume For low PO₂: increase FiO₂ and PEEP


- Obtain ABG prior to intubation, 30 minutes following intubation, and 30 minutes after vent changes.
- Goal plateau pressure < 30 cm H₂O; decrease Vt to lower plateau pressure.
 Obese patients may require higher plateau pressure.

Target pH > 7.30; increase RR to control hypercapnia.

Avoid intubation if possible in patients with obstructive lung disease; maximize use of NIPPV.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 12/7/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Travis_Nelson@ykhc.org or Leslie_Hermann@ykhc.org.








Return to Table of Contents.


If patient is an inmate: Physician must contact the Department of Corrections On Call line so that arrangements can be made for public safety.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 2/5/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Chloe_Wurr@ykhc.org.



This guideline is designed for the general use of most patients but may need to be a dapted to meet the special needs of a specific patient as determined by the medical practitioner. App roved by MSEC 11/2/21. Click here to see the supplemental resources for this guideline.

If comments about this guideline, please contact Ellen_Hodges@ykhc.org.




Return to Table of Contents



Clinical Protocol

Procedural Sedation and Analgesia Outside the OR






Procedural Sedation and Analgesia Outside the OR

Agent	Bolus Dose	Titration Dose	Onset	Duration	Reversal Agent	Comments
	Patients >10 years: 0.2 mg/kg	0.05 mg/kg Q3-5 min	30-60 seconds	3-5 minutes		 No analgesic effect. Use IBW if BMI>30. Consider lower dose (0.1 mg/kg) for age >60 years, concurrent opioids, or if recent alcohol use.
Etomidate	Patients ≤10 years: 0.2 mg/kg (0.1-0.3 mg/kg) Slow IV push over 30- 60 seconds.	0.05 mg/kg Q3-5 min	30 seconds	2-10 minutes	Time	 Administer via larger vessel. (antecubital or larger). Precautions: 30% have myoclonus with transient skeletal/eye movements.
	<u>Adults</u> : 1-2 mg/kg IV over 1-2 min 4-5 mg/kg IM		30 seconds 3-4 min	10-20 min 20-30 min	• Time	 Local anesthetic (eg. lidocaine) can increase effective duration. Consider lower dose range for >60 years,
Ketamine	<u>Children >3 mo</u> : 1-2 mg/kg IV over 1 min		30-120 seconds	20-60 min	• For laryngospasm: Succinylcholine 0.25-0.5 mg/kg IV or	concurrent opioids/alcohol. • Consider dosing by adjusted body weight if BMI>30. • Precautions: emergence reactions (treat with
	4-5 mg/kg IM 5 mg/kg PO		5-10 min 20-45 min	30-90 min 60-120 min	3-4 mg/kg IM	 benzodiazepines), nausea/vomiting (pre-treat with ondansetron), transient increase in salivation. Contraindications: pregnancy, age <3 months.
	<u>Patients >2 yrs</u> : Ⅳ load 0.5-1 mg/kg	Repeat 0.1-0.3 mg/kg Q30-60 seconds	30-60 seconds	3-10 min		 No analgesia. Consider low dose for age >60, concurrent opioids/alcohol. Consider dosing by adjusted body weight if BMI>30. Separate administration of opioid and propofol by >20 minutes to decrease respiratory depression.
Propofol	<u>Children 6 mos – 2 yrs</u> : IV load 1-2 mg/kg	Repeat 0.1-0.3 mg/kg Q30-60 seconds Max cumulative dose 3 mg/kg			Time	 Pre-oxygenate with high flow supplemental oxygen at least 3 minutes prior to procedure. Precautions: burning sensation during administration, hypotension, ↓CO, or bradyarrhythmias. High risk of respiratory depression/failure. Contraindications: allergies to egg, soybean, fat
	Adults:					emulsion.
Morphine	1-4 mg IV 10 mg PO		5-10 min IV 30 min PO	3-5 hours	Naloxone 0.1 mg/kg IV. May repeat	 Reduce dose when combining with a benzodiazepine. As opioids provide sedation and analgesia,
	Pediatrics: 0.05-0.1 mg/kg IV Max 4 mg		5-10 min	2-3 hours	Q2 minutes.	administer them prior to benzodiazepines.
	Adults: 0.5 mcg/kg if given with other sedatives	May repeat dose Q2min until desired sedation	<1 min		Naloxone	 Reduce dose when combining with a
Fentanyl	0.5-1 mcg/kg Max 100 mg	and analgesia achieved			0.1 mg/kg IV. May repeat Q2 minutes.	benzodiazepine. • As opioids provide sedation and analgesia, administer them prior to benzodiazepines.
	Pediatrics: 1 mcg/kg IV up to 50 mcg/dose		3-5 min	30-60 min		
Midazolam	<u>Adults</u> : 2-5 mg IV	May repeat dose Q2min until adequate sedation. Max 0.3 mg/kg.			Flumazenil 0.01 mg/kg (up to 0.2 mg) IV over 15	Consider lower dose range for >60 years,
	<u>Pediatrics (6 mos - 12 yrs</u>): 0.2-0.3 mg/kg/dose IN 0.05 mg/kg IV	May repeat dose Q5min until max dose of 0.5 mg/kg is reached. Age <5 max 6 mg; age >5 max 10 mg.	3-5 min	15-20 min	seconds. May repeat Q1 minute.	concurrent opioids/alcohol. • Watch for dose-related hypotension.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 4/6/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Tara_Lathrop@ykhc.org.

25



Continue to reassess frequently while awaiting admission or transfer.

Tara_Lathrop@ykhc.org.



Clinical Guideline Sepsis Antibiotics (Adult)

Empiric Antibiotic Recommendations by Source of Infection If possible, first dose of antibiotics should be administered as a 30 minute infusion to reduce time to therapeutic concentration. **Unknown Source** Vancomycin¹ 25-30 mg/kg loading dose Gentamicin² 7 mg/kg IV Q24h. followed by 20 mg/kg Q8-12h. Piperacillin-tazobactam³ 4.5 grams IV Q8h. Consult pharmacy for max dosing. Max dose 2 grams. AND AND OR OR OR If in shock: Cefepime 2 grams IV Q8h. Levofloxacin 750 mg IV Q24h. Linezolid 600 mg IV Q12h. Community-Acquired Pneumonia Ceftriaxone 1 gram IV Q24h. If at risk for Levofloxacin 750 mg IV Q24h. (2 grams if > 80 kg.)aspiration, AND OR Metronidazole 500 mg IV Q8h. OR consider Azithromycin 500 mg PO/IV Q24h. Ampicillin-sulbactam 3 grams IV Q6h. adding: Hospital-Acquired Pneumonia or High Risk for Multi-Drug Resistant (MDR) Organisms Vancomycin¹ 25-30 mg/kg loading dose Levofloxacin 750 mg IV Q24h. Piperacillin-tazobactam³ 4.5 grams IV Q6h. followed by 20 mg/kg Q8-12h. OR AND AND Max dose 2 grams. OR Gentamicin² 7 mg/kg IV Q24h. OR If in shock: Cefepime 2 grams IV Q8h. Consult pharmacy for max dosing. Linezolid 600 mg IV Q12h. **Meningitis** Vancomycin¹ 25-30 mg/kg loading dose lf >50 Dexamethasone 10 mg IV **Ceftriaxone** Ampicillin AND AND followed by 20 mg/kg Q8-12h. years, prior to antibiotics. 2 grams IV Q12h. 2 grams IV Q6h. Max dose 2 grams. ADD Urinary Tract Infection If urological interventions or MDR Gentamicin² 7 mg/kg IV Q24h. risk factors, consider adding: AND If at risk of ESBL, ADD: **Ceftriaxone** Consult pharmacy for max dosing. Piperacillin-tazobactam³ 1 gram IV Q24h. consider <u>Meropenem</u> 3.375 grams IV Q6h. OR adding: (2 grams if > 80 kg.)500 g IV Q8h. OR Levofloxacin 750 mg IV Q24h. Cefepime 1 gram IV Q6h. Intra-abdominal or Pelvic Infection Cefepime 1 gram IV Q6h. Ciprofloxacin 400 mg IV Q12h. Piperacillin-tazobactam³ OR AND OR AND 3.375 grams IV Q6h. Metronidazole 500 mg IV Q6h. Metronidazole 500 mg IV Q8h. Skin and Soft Tissue or Necrotizing Infections Piperacillin-tazobactam³ 3.375 grams IV Q6h. AND IF PURULENT: IF NON-PURULENT: Clindamycin 900 mg IV Q8h. Vancomycin¹ 25-30 mg/kg loading dose Cefazolin 2 grams IV Q8h. lf OR followed by 20 mg/kg Q8-12h. necrotizing, OR Max dose 2 grams. Ceftriaxone 1-2 grams IV Q24h. ADD: OR Ceftriaxone 2 grams IV Q12h. Ampicillin-sulbactam 3 grams IV Q6h. AND Metronidazole 500 mg IV Q6h. Neutropenic Cancer Patients (ANC < 500) If concerned Piperacillin-tazobactam³ Vancomvcin¹ 25-30 mg/kg loading dose for HSV or Acvclovir 4.5 grams IV Q6-8h. AND followed by 20 mg/kg Q8-12h. VZV, 10 mg/kg Q8h. OR Max dose 2 grams. Consult pharmacy for max dosing. consider Cefepime 1 gram IV Q6h. adding: This guideline is designed for the general use of most patients but may need to Linezolid may be substituted for vancomycin in patients with relative contraindication to be adapted to meet the special needs of a specific patient as determined by the vancomycin for high risk for acute kidney injury. medical practitioner. ² Gentamicin dosing based on ideal body weight. Approved by MSEC 7/12/17. May substitute ampicilin-subactam 3 gram IV Q6h for piperacilin-tazobactam if not concerned for pseudomonas. f comments about this guideline, please contact Tara_Lathrop@ykhc.org





Sepsis Vasoactive Medications (Adult)

	<u>Vasopressors</u>
All vasoactive medications should be infused via central line with the kg/minute.	exception of dopamine, which can be infused via a peripheral IV at rates less than 10 mcg/
Norepinephrine 8-12 mcg/min IV initial infusion rate.	First-line vasopressor of choice in sepsis.
Epinephrine 1-10 mcg/min initially, titrated to effect.	May be added or used in place of norepinephrine to maintain adequate BP.
• Dopamine 2-20 mcg/kg/min.	Second-line option in highly select patients as it causes more tachycardia.
 Phenylephrine 100-180 mcg/min IV initial infusion until stabilized. Titrate to goal of 60-200 mcg/min. (Max dose range 80-360 mcg/min.) 	Can be used as salvage therapy for refractive hypotension associated with tachycardia.
• Vasopressin 0.03-0.04 units/min.	May be added to norepinephrine to increase MAP or decrease norepinephrine dose. DO NOT use as a single agent.
Dobutamine 2-20 mcg/kg/min IV infusion.	May be used for inoptropic support in the presence of severe myocardial dysfunction or hypoperfusion with depressed cardiac output.

Corticosteroids

Corticosteroids should NOT be administered for the treatment of sepsis in the absence of shock. Steroids are beneficial in those experiencing adrenal insufficiency in the presence of septic shot; however ACTH testing is not routinely recommended in adult patients. If hemodynamic stability is not achieved after adequate fluid resuscitation and vasopressor therapy, the use of IV hydrocortisone alone at a dose of 200 mg/day can be considered regardless of adrenal insufficiency status. Hydrocortisone should be tapered when vasopressors are no longer required.







Amy_Carson-Strnad@ykhc.org.




Clinical Guideline

Status Epilepticus Treatment (Adult)







Indications for Admission or Transfer: -Status epilepticus -Cluster of seizures -Increased intracranial pressure -CNS infection -Structural lesion -Patient does not return to baseline mental status


This guideline is designed for the general use of most patients but may need to be a dapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 8/3/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Jennifer_Hampton@ykhc.org.





Yukon-Kuskokwim

Abuse/Assault	
Sexual Assault (≥18 Years)	33
Strangulation	34
Suspected Physical Abuse Procedure (Pediatric)	35
Suspected Sexual Abuse Procedure (Pediatric)	36



SART Team Members

Law enforcement

 SANE/SAFE (Sexual Assault Nurse Examiner/Sexual Assault Forensic Examiner)
 TWC advocate

Contact Information

<u>Tundra Women's Coalition</u> :
Business Line: (907) 543-3444
Crisis Line: (907) 543-3456
Toll Free: (800) 478-7799
Law Enforcement:
Bethel Police Department: (907) 543-3781
Bethel Post of Alaska State Troopers: (907) 543-2294
Aniak Post of Alaska State Troopers: (907) 675-4459
Emmonak Post of Alaska State Troopers: (866) 949-1303
St. Mary's Post of Alaska State Troopers: (907) 438-2019
National Sexual Assault Helpline:
(800) 656-4673

Available 24 hours a day, 7 days a week.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 12/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Jennifer_Prince3@ykhc.org.



Strangulation

Goals	Patient presents with concern for strangulation				
1. Evaluate carotid and vertebral arteries for					
injuries. 2. Evaluate bony/cartilaginous and neck soft tissue structures.	Are ANY of the following present?				
3. Evaluate brain for anoxic injury.	 Airway: subcutaneous emphysema (can be a sign of tracheal or laryngeal rupture) Neurological: loss of consciousness, seizures, mental status changes, amnesia, cortical blindness, 				
Note: Life-threatening injuries can be present up to one year after strangulation event.	 movement disorders, stroke-like symptoms HEENT: Visual changes: spots, flashing lights, tunnel vision, etc. Facial, intra-oral, or conjunctival petechial hemorrhage Odynophagia Neck: 				
Helpful Links S/Sx strangulation in <u>adults</u> and <u>children</u> Physiological consequences timeline 	 Neck: Ligature mark, neck contusion, soft tissue injury, swelling, carotid tenderness, etc. Dysphonia/aphonia, hematoma, laryngeal fracture, recurrent laryngeal nerve injury Bladder or bowel incontinence Pulmonary: dyspnea, phrenic nerve injury 				
Rule Out Life-Threatening Injuries • If GFR ≥30: CT angio of carotid/vertebral ari is the gold standard for evaluation of vessels cartilaginous structures but is not very sensitive tissue trauma. • If GFR <30: non-contrast CT of neck. This significant to the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive than CT angio for vessel injury but of the sensitive the sensiti	teries. This and bony/ ve for soft tudy is less	How recent was≥ 4 event? 	ago AND a sa	able home monitor afe place to go to YesNo	0?
visualization of bony and cartilaginous structu I Injury identified	Obsection inpatient	★ # # #	to ED if any neu	tions to return urological	 Consider discharge to TWC. May call TWC
Consult trauma surgery and plan to tra Consider ENT consult for laryngeal trai with dysphonia.			signs/symptoms dysphonia, ody dysphagia, or v occur or worser • Give custom S	s, dyspnea, nophagia bice changes h. Strangulation	Crisis Line (543- 3456) for assistance with safe shelter. • Also may call
			Patient Education	on handout.	SART on call at 545-4238 for further assistance.

Tundra Women's Coalition (TWC)

- Crisis Line: 543-3456
- Main office: 543-3444
- On-call advocate: 545-4328

Services Provided by TWC

- Emergency shelter
- Hospital accompaniment
- Information about community resources
- Legal advocacy
- Violent crime compensation
- Funds for emergency air or cab transportation

If patient would like to report incident:

- If occurred in a village: Alaska State Troopers 543-2294
- If occurred in Bethel: Bethel Police Department 543-3781

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 11/2/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Jennifer_Prince3@ykhc.org.


Use the following autotexts in your documentation: • ..hpiStrangulation • ..physStrangulation



Jennifer_Prince3@ykhc.org.


Yukon-Kuskokwim HEALTH CORPORATION Suspected Physical Abuse Procedure (Pediatric)


Clinical Guideline





Suspected Sexual Abuse Procedure (Pediatric)









Yukon-Kuskokwim


Cardiovascular	
Acute Coronary Syndrome (MI)	38
Aspirin for Adults >40 Without Known Cardiovascular Disease	42
Congestive Heart Failure	43
Hypertension	45
Post-MI Management	46



Yukon-Kuskokwim

Clinical Guideline

Acute Coronary Syndrome (ACS) Management





Yukon-Kuskokwim HEALTH CORPORATION

Acute Coronary Syndrome (ACS) Management

<u>Nitroglycerin (NTG)</u>
 Contraindications:
PDE-inhibitor use,
cardiogenic shock, RV
infarct, sBP<90,
marked tachycardia or
bradycardia.
 Sublingual dosing:
0.4 mg SL Q5 minutes
up to three doses
 <u>IV dosing</u>: start at
10-20 mcg/min, titrate
Q3-4 minutes to
typical range 60-100
mcg/min

Beta-Blockers • No evidence of benefit from routine immediate betablocker. • In dicated for HTN

and/or ongoing ischemia refractory to NTG. • <u>Contraindications</u>: cardiogenic shock, RV

infarct, symptomatic asthma. • <u>Cautions</u>: risk for cardiogenic shock

(bradycardia, HR>110, sBP<120, age>70, in creased time since STEMI onset), inferior MI, controlled asthma.

	Emergency Department Medication Summary					
		STEMI <12 hours	STEMI >12 hours	NSTE-ACS		
	Oxygen	Maintain SpO ₂ 90-96%	Maintain SpO ₂ 90-96%	Maintain SpO ₂ 90-96%		At time
	Nitrates (<i>prn</i> pain, HTN)	Sublingual or drip	Sublingual or drip	Sublingual or drip	┥	1e of
	Fibrinolytic	Tenecteplase See page 1, Box 5	Not indicated	Not indicated		of Dx unless
ß	Aspirin	325 mg PO (chewed)	325 mg PO (chewed)	325 mg PO (chewed)	┥	
telet agents	P2Y ₁₂ receptor blocker	Clopidogrel Age ≤75: 300 mg PO Age >75: 75 mg PO	Clopidogrel 600 mg PO	Consult cardiology.	-	contraindicated
Antiplatelet	Glycoprotein IIb/IIIa inhibitor	Eptifibatide (Integrilin) Per cardiologist. Typically given after PCI.	Eptifibatide (Integrilin) Per cardiologist. Typically given after PCI.	Eptifibatide (Integrilin) Per cardiologist. Typically given after PCI.		ted
	Anticoagulation	Enoxaparin (see table for dose)	Enoxaparin (see table for dose)	Enoxaparin (see table for dose)		
-	Beta-blocker	Metoprolol 5 mg IV <i>pm</i> Q5 minutes (max 15 mg)	Metoprolol 5 mg IV <i>pm</i> Q5 minutes (max 15 mg)	Metoprolol 5 mg IV <i>pm</i> Q5 minutes (max 15 mg)		
Morphine No longer routinely given; associated with increased mortality. Reserve for significant pain refractory to NTG and beta-blocker.						

Enoxaparin Dosing			
	Age <75 years and STEMI	Age ≥75 years and STEM	Any age and NSTE-ACS
Creatinine clearance ≥30 mL/min	30 mg IV + (1 mg/kg SC now then Q12h) Max dose 100 mg	0.75 mg/kg SC Q12h Max dose 75 mg	1 mg/kg SC now then Q12h
Creatinine clearance <30 mL/min	30 mg IV + (1 mg/kg SC now then Q24h) Max dose 100 mg	1 mg/kg SC Q24h Max dose 100 mg	1 mg/kg SC now then Q24h
NOTE: Enoxaparin and unfractionated heparin are NOT dialyzable; ESRD/dialysis patients should receive fondaparinu		l Id receive fondaparinux.	

which is not on the YKHC formulary. Discuss with cardiologist if appropriate.

Inpatient Medication Summary		
NOTE: The following table is meant to be a basic reference as a starting point. Please consult Cardiology for full recommendations in all ACS patients.		
ACE-inhibitor	Lisinopril 2.5 – 5 mg PO daily Give unless contraindicated. Typically started prior to hospital discharge. Unclear if ED initiation is beneficial.	
Statin	Atorvastatin 80 mg PO daily Give unless contraindicated. Typically started prior to hospital discharge. Unclear if ED initiation is beneficial.	
Beta-blocker	Metoprolol XL 25-50 mg PO Q12-24h <i>pm</i> Give unless contraindicated. Typically started prior to hospital discharge.	
Clopidogrel	75 mg PO daily	
Aspirin	81 mg PO daily	
Enoxaparin	Dose above. Consult Cardiology for duration.	

This guideline is designed for the general use of most patients but may need to be a dapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 12/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Megan_Young@ykhc.org and Andrew_Swartz@ykhc.org.



Yukon-Kuskokwim Clinical Guideline HEALTH CORPORATION Acute Coronary Syndrome (ACS) Management

Fibrinolytic Checklist				
INDICATIONS (initial yes or no)				
YES	NO			
		Presentation consistent with acute coronary syndrome (coronary artery occlusion)		
		AND at least one of the following: • 1 mm J-point elevation in two contiguous leads (other than V ₂ -V ₃) • In leads V2-V3 Men ≥ 40 years: ≥ 2 mm J-point elevation Men <40: ≥ 2.5 mm J-point elevation Women: ≥ 1.5 mm J-point elevation		
ABSOLUTE (CONTRAINDICAT	FIONS (initial yes or no)		
YES	NO			
		History of <u>any</u> intracranial hemorrhage		
		History of prior ischemic stroke, significant closed head injury or facial trauma, or intracranial or spinal surgery in the previous three months		
		Presence of a cerebral vascular malformation		
		Presence of a primary or metastatic intracranial malignancy		
		Symptoms or signs suggestive of an aortic dissection		
		Any bleeding diathesis		
		Any active bleeding that is severe or has high potential for life-threatening blood loss; this does not include menstrual bleeding		
		sBP > 180 and/or dBP >110 at presentation in patient at low risk of cardiac death (age < 55, no prior MI, and Killip class I).		
		Terminal illness, defined as end of life care or documented/expressed patient wish to abstain from high risk or invasive procedures		
RELATIVE CO	ONTRAINDICAT	ONS (initial yes or no) – If any of below are present, used shared decision making with patient.		
YES	NO			
		Age 65-74 (ICH relative risk 3.12 [2.54-3.83]); Age ≥ 75 years (ICH relative risk 5.40 [4.40-6.63])		
		History of chronic severe poorly controlled HTN		
		sBP > 180 and/or dBP >110 at presentation in patient at high risk of cardiac death (age \geq 55, Hx prior MI, or <u>Killip class \geq II).</u>		
		History of ischemic stroke more than three months ago		
		Dementia OR any known intracranial disease that is not an absolute contraindication		
		Traumatic or prolonged (>10 minutes) cardiopulmonary resuscitation		
		Major surgery in the previous three weeks		
		Internal bleeding in the previous 2-4 weeks		
		Active peptic ulcer		
		Non-compressible vascular punctures		
		Pregnancy		
		Current warfarin therapy (the risk of bleeding increases as the INR increases)		

This checklist is advisory for clinical decision-making and may not be all-inclusive. Risks and benefits will need to be assessed individually.

Physician signature: _

Printed name:

_ Date and time: _

Place patient ID sticker here.



Acute Coronary Syndrome (ACS) Management

PROCEDURE CONSENT		
I hereby authorize following operation or procedure	and such assistants as he/she may designate, to perform the	
TECHNICAL DESCRIPTION	Intravenous thrombolytic therapy for acute STEMI (ST-elevation myocardial infarction).	
LAY DESCRIPTION	Give clot-dissolving medication through an IV to dissolve the clot which is causing a heart attack.	
has discussed with me the information briefly summarized below:		
BENEFITS • When PCI is not available within two hours, thrombolytic medication is the "standard of care" for achieving coronary r within 12 hours of acute STEMI onset. • When administered within 6 hours of pain onset, about 1 in 40 persons will have their life saved. • When administered between 6-12 hours after pain onset, about 1 in 60 persons will have their life saved. • Decreased risk of developing heart failure. • A STEMI patient who receives thrombolytic medication is about 3-5 times more likely to have their life saved than to bleeding (see below).		
	 About 1 in 100 persons will experience non-life-threatening bleeding. About 1 in 100-250 persons will experience bleeding into the brain which usually results in either death or significant disability. 	
RISKS OF NOT HAVING THE PROCEDURE	 Higher risk of death. Higher risk of developing heart failure. 	
ALTERNATIVE TREATMENTS	None are available at this facility.	


Patient signature:	Witness signature:
Printed name: Date and time:	Printed name: Date and time:
Physician signature:	Witness signature:
Printed name: Date and time:	Printed name: Date and time:

Place patient ID sticker here.



Π

Yukon-Kuskokwim HEALTH CORPORATION




Notes

Aspirin produces significant reductions in mortality amongst survivors of cardiovascular disease, but its role in the primary prevention of cardiovascular disease amongst healthy adults is less clear.

See <u>table under "Possible Benefits"</u> for summary of RCT data for low dose aspirin in the primary prevention of cardiovascular disease.








This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 7/12/17. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.




Congestive Heart Failure, page 2



Calcium channel blocker contraindicated in Stage C. **Aldosterone antagonists:
Use for estimated creatinine clearance > 30 and potassium < 5.
Check BMP at baseline, day 2, day 7, monthly x3, Q3 mo x1 year, then Q6 mo

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 7/12/17. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.



 Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009 Mar;122(3):290-300.


Marsha_Dunkley@ykhc.org.



Yukon-Kuskokwim

Clinical Guideline

Post-MI Management








Yukon-Kuskokwim
HEALTH CORPORATIONGastrointestinal, Hematologic, &
Endocrine Guidelines

Gastrointestinal, Hematologic, & Endocrine	
Diabetes, Type 2	48
Dyspepsia/H pylori (Adult and Pediatric)	50
Iron Infusion for Chronic Iron-Deficiency Anemia (Adult and	
Pediatrics)	51
Osteoporosis Screening and Treatment	52



Clinical Guideline Diabetes Mellitus, Type 2



Diabetes Resources

- Diabetes Self-Management Education and Support (DSMES)
- Medical Nutrition Therapy (MNT)
- Continuous Glucose Monitor (CGM): usually for those with A1c >9,
- those on insulin, or those not achieving A1c goals. See <u>ADA paper</u>.
 Other (DM support group, exercise physiology for exercise Rx)


Abbreviations/Acronyms

ADA = American Diabetes Association ASCVD = Arteriosclerotic cardiovascular disease BH = Behavioral Health CKD = chronic kidney disease CMP = Complete Metabolic Profile DM = Diabetes mellitus FPG = Fasting Plasma Glucose Hgb A1c or A1c for short = Hemoglobin A1c or glycosylated hemoglobin HTN = Hypertension OGTT = Oral Glucose Tolerance Test OSA = Obstructive sleep apnea PG = Plasma Glucose RPG = Random Plasma Glucose SMART = Specific, Measurable, Achievable, Realistic, Time-limited

• Self-care through sleep hygiene, mindfulness, nature, and similar efficacious stress reduction techniques.

- Advise developing a positive, supportive social network.
 Use patient centered SMART goals, including consideration
- of individualized targets, impact on weight, hypoglycemia risk, side effect profile of medications, and complexity of regimen. Choose regimen to optimize adherence and persistence.
- Exercise is medicine: Titrate to 150 min/week minimum.
- Advise 7-10% weight loss if obese.

Recommend traditional Alaska Native diet with emphasis on maximizing plants and high fiber foods.




Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Elizabeth_Tressler@ykhc.org.



Yukon-Kuskokwim

Clinical Guideline

Type 2 Diabetes Mellitus Management




This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 9/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact


Elizabeth_Tressler@ykhc.org.






Clinical Guideline





This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 4/26/18. Click <u>here</u> to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.



clinic for further evaluation.

Oncology at (907) 929-3773.


Iron Replacement Dose Calculation	Side Effects/Reactions
Total Iron Replacement Dose (in mg) = $0.6 x$ weight $x \left[100 - \left(\frac{actual \ hemoglobin}{desired \ hemoglobin} \right) x \right]$	years. Consult pediatric nematologist for
 For pediatric patients: Using iron sucrose, this dose should be given in aliquots of 5-7 mg/kg until the full replacement given. Max dose is 100 mg for initial dose and 300 mg for repeat doses. Per Pediatric Hematology, may give children two iron sucrose doses 24 hours apart and then regiving more frequent dosing or more than two daily doses in a row results in decreased absorpt side effects in children. Eor adult patients: Dose is typically iron sucrose 300 mg IV daily x3 doses. 	epeat in 1-2 weeks.
	• For IV infiltrates, place cold pack.

Last reviewed 7/6/21. Click here to see the supplemental resources for this guideline. ANMC Adult Hematology Oncology can be reached at (907) 729-1180. If comments about this resource, please contact Leslie_Herrmann@ykhc.org.

51




Clinical Guideline Osteoporosis Screening



At Risk Medications


- Systemic steroids >3 months
- Methotrexate
- Aromatase inhibitor
- Selective estrogen receptor modulator
- Proton pump inhibitor
- Heparin
- SSRI



Recommended Calcium Intake		
Age	<u>Sex</u>	RDA mg/day
9-18	M+F	1300
19-50	M+F	1000
51-70	Μ	1000
51-70	F	1200
>71	M+F	1200

Recommended Vitamin D Intake		
Age	<u>Sex</u>	<u>RDA IU/day</u>
14-70	M+F	600
>71	M+F	600

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 9/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact David_Compton@ykhc.org.



Return to Table of Contents.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 9/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact David_Compton@ykhc.org.





Yukon-Kuskokwim

Infectious Disease	
Amoxicillin Allergy Trials (Pediatric)	55
Botulism	
Bronchiectasis/Chronic Cough (<18 years)	
Bronchiolitis/Wheezing (3-24 months)	58
Croup/Stridor (6 months – 3 years)	59
Fever (0-90 days)	60
Influenza (Adult and Pediatric)	61
Lymphadenitis, Acute Cervical (Pediatric)	62
Otitis Media, Acute (3 months - 12 years)	63
Peritonsillar Abscess (Adults and Pediatric)	64
Pharyngitis (Adults and Pediatric)	65
Pneumonia (Adult)	66
Pneumonia (>3 months)	67
Procalcitonin in Lower Respiratory Tract Infections (Adult)	68
Rabies	69
Sepsis (Adult)	70
Sepsis Medications (Adult)	71
Sepsis/Septic Shock (Pediatric)	73
Sexually Transmitted Infections	74
Sinusitis (>4 years)	
Skin and Soft Tissue Infection (Adult and Pediatric)	77
Tuberculosis, Active Pulmonary (≥14 years)	79
Tuberculosis, Latent (≥14 years)	80
Tuberculosis Evaluation and Treatment (<14 years)	81
UTI (Adult)	82
UTI (3 months – 5 years)	83
Varicella, Suspected	



Clinical Guideline

Amoxicillin Allergy Trials (Pediatric)



 Only 4-9% of those...labeled [penicillin-allergic] are currently allergic. It is important to identify those who are not allergic, because children mislabeled as penicillin-allergic have more medical visits, receive more antibiotic prescriptions, and have longer hospitalizations with more antibiotic-related complications.¹

• Up to 10% of children develop rashes while receiving antibiotics. Most are diagnosed...as allergic to the implicated antibiotic, and most continue to avoid the suspect antibiotic in favor of alternatives, which may be less effective, more toxic, and more expensive.²

• Do not label a patient as allergic to penicillin/ amoxicillin unless he or she has true hives, anaphylaxis, or a life-threatening reaction. Please include photos of rashes in RAVEN.

Children labelled as allergic to penicillin/amoxicillin often carry that label for the rest of their lives.
Please consult a pediatrician with any questions.

Anaphylaxis

• Acute onset – several minutes to hours from exposure.

 Generalized hives, pruritis or flushing, swelling of lips/tongue/uvula, and at least one of the following:

Dyspnea, bronchospasm, stridor Hypotension

Evidence of hypoperfusion of endorgans

Persistent crampy abdominal pain, and/or vomiting or diarrhea

Hives vs Viral Rash

 True hives are raised, <u>itchy</u>, larger than dime-sized, come and go, move around the body, and change shape and size. True hives are uncomfortable. Ask if the rash bothered the child.


• Keep in mind that many parents refer to any rash as "hives." Get a description every time.

• A viral exanthem is typically diffuse, fine, pinpoint red dots and can be dense, coalesced, larger raised lesions. The rash typically covers the face and chest but can cover the whole body. The rash typically worsens and takes days to clear.

References

1. Kelso JM. "Provocation challenges to evaluate amoxicilin allergy in children." JAMA Pediatrics 2016;170(6):e160282.

 Mill C, et al. "Assessing the diagnostic properties of a graded oral provocation challenge for the diagnosis of immediate and nonimmediate reactions to amoxicillin in children." JAMA Pediatrics. 2016;17(6):e160033.



Amoxicillin Trial Procedure²

Use AMB Amoxicillin Trial Power Plan.

1. Obtain VS. Perform physical exam, including lung exam. Have appropriate dose of EpiPen or epinephrine. Epinephrine (1 mg/mL): 0.01 mg/kg (or 0.01 mL/kg) IM Q5-15 minutes. Per AAP recommendations:

- 7.5-25 kg: use EpiPen Jr (0.15 mg)
- $\bullet \ge 25$ kg: use EpiPen (0.3 mg)
- 2. Calculate weight-based dose of amoxicillin. Give patient 10% of that dose.
- 3. Place patient in nearby room and instruct caregiver to notify staff of any changes in status.
- If no reaction by 20 minutes, give patient remaining 90% of weight-based dose of amoxicillin.
- The reaction by 20 minutes, give parent remaining 90% of weight-based dose of antoxicilin.
 Observe another 60 minutes. If no reaction, check VS and physical exam. If all stable, discharge home with regular course of drug.
- 6. Give patient and family amoxicillin trial education sheet.

7. Update allergy alert in RAVEN. Click the allergy in the banner. Right click over the drug name and choose "cancel." On the "reason" drop-down menu, choose "OK on Retrial."

Notes:

• If patient is on a beta-blocker, stop this for 24 hours prior to procedure, if possible. Beta-blockers can interfere with treatment for anaphylaxis, if it occurs.


• Ensure that patients with asthma have optimal control prior to this procedure.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 8/3/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.

Clinical Guideline



Suspected Botulism



<u>Resources</u>

 AK State Office of Epidemiology Website: -907-269-8000 (M-F, 8-5) and 800-478-0084 (after hours)
 State Lab Website: -1-855-222-9918
 Division of Public Health Healthcare Provider Checklist

Note: Botulism toxin only causes flaccid paralysis. Patients are awake, alert, and aware. Procedures should be explained and appropriate pain control and sedation for intubated patients should be provided.


Infant Botulism:

This is rare, with only 5 reported cases in AK in the past 65 years. If suspected, see Epi Procedure Manual, Botulism at State website.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 12/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Lisa_Evans@ykhc.org.




Bronchiectasis/Chronic Cough (<18 years)




This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 9/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.



58








Abscess

Note: if prolonged symptoms (>3-5 days without any improvement), consider diagnosis other than croup.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 8/3/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.



Return to Table of Contents.

Yukon-Kuskokwim HEALTH CORPORATION

Influenza (Adult and Pediatric)

Testing Recommendations		
Suspected Influenza in the Ambulatory Setting: • Patients considered <u>High Risk for Complications</u> (See below.) • Adults >65 years of age • Children <2 years of age • Patients with complicated influenza-like illness that may warrant treatment • Individuals with febrile illness of unclear etiology or as part of a sepsis evaluation *It is not recommended to perform testing in most ambulatory patients who present with uncomplicated flu-like illness.	Suspected Influenza in the Inpatient Setting: <u>All</u> patients admitted with febrile illness or respiratory symptoms should be tested.	
 High Risk for Influenza Complications: Chronic Pulmonary Disease (including asthma and pediatric patients with chronic Pulmonary Disease (except for hypertension) Diabetes Mellitus, or other metabolic disorders Immunosuppressed (chronic steroids/biologics, chemotherapy, AIDS, etc.) Pregnant or Postpartum up to 2 weeks Morbid Obesity (BMI >40) <19 years of age receiving long-term aspirin therapy Renal, hepatic, hematologic impairment/disease Neurologic and neurodevelopment conditions (cerebral palsy, epilepsy, modeling) 		
Treatment Recommendations		
Indications for Treatment All patients with confirmed influenza, regardless of timing, who: Have severe, complicated, or progressive illness. Require hospitalization. 	Treatment NOT Recommended• Non-institutionalized (hospital or other health care facility) patients age 2-64years not at high risk for influenza complications.• Patients with uncomplicated illness after 48 hours of symptom onset.	

Are high risk for influenza complications (see above).

· Can be considered based on supply and clinical judgment in low risk patients

within 48 hours of symptom onset.

Chemoprophylaxis Recommendations

Chemoprophylaxis of household members is not routinely recommended except for:

-Medically high-risk (see above) close contacts within 48 hours of exposure

* For neonates born to mothers with influenza, defer to Seattle Children's Hospital Infectious Disease Physician Consult Line for formal recommendations: (206) 987-7777.


Influenza Treatment Dosing for Oseltamivir

	Age/Weight	Dose	Renal Dose Adjustments	Duration	
Neonates	Neonates PMA <38 weeks: 1 mg/kg/dose PO q12hr PMA 38-40 weeks: 1.5 mg/kg/dose PO q12hr PMA >40 weeks: 3 mg/kg/dose PO q12hr >2 weeks: 3 mg/kg/dose PO q12hr Confirm with Seattle Children's Hospital Infectious Disease Physician Consult Line (206) 987-7777.			5 days	
Infants	Term, 3-8 months 9-11 months	3 mg/kg/dose PO q12hr 3.5 mg/kg/dose PO q12hr	CrCl <30mL/min: usual dose given q24hr *additional dose adjustment needed for hemodialysis (consult pediatric nephrology in all cases)	5 days	
Children 1-12 years	<15 kg 15-23 kg 23-40 kg	30 mg PO q12hr 45 mg PO q12hr 60 mg PO q12hr		5 days	
Adults and Children ≥ 12 years	>40 kg or >12 years	75mg PO q12hr	CrCl 30-60 mL/min: 75mg PO q24hr CrCl 10-30mL/min: 30 mg PO q24hr Hemodialysis: Consult nephrology	5 days	

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 4/14/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Megan_Young@ykhc.org.




Lymphadenitis, Acute Cervical (Pediatric)





Clinical Guideline


Otitis Media, Acute (3 months – 12 years)



This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 2/5/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.

When to Refer to ENT


- 3 episodes of AOM in 6 months • 4 episodes of AOM in 12 months
- OME or otorrhea for ≥3 months
- Hearing loss >20 dB



Ampicilli	ics for peritonsillar abscess : n-sulbactam 3 grams IV q6h for adults and 50 mg/kg/dose on ampicillin, max 3 grams) IV q6h for pediatrics.
Clindam	l <u>in allergic</u> : ycin 600 mg IV q6h for adults and 13 mg/kg/dose (max 600 mg) or pediatrics.
	<u>e disease</u> : r coverage for MRSA with vancomycin.
Amoxicil	<u>le to transition to oral</u> : lin-clavulanate 875 mg PO BID for adults and 45 mg/mg/dose 5 mg) PO BID for pediatrics.
Clindam	l <u>in allergic</u> : ycin 300 mg PO 4 times daily for adults and 13 mg/kg/dose PO daily for pediatrics.
Total du	ration of treatment: 14 days

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 4/14/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Elizabeth_Bates@ykhc.org.





Considerations:

Consider testing for oral GC/CT in at-risk populations.

Testing for Group A streptococcal (GAS) pharyngitis is NOT


recommended for acute pharyngitis with clinical features that strongly suggest viral etiology.


• Routine use of back-up cultures for those with a negative rapid test is not needed for adults; there is a low incidence of GAS in adults and risk of subsequent acute rheumatic fever is exceptionally low.

• It is NOT recommended to test for GAS in patients under the age of 3; the risk of rheumatic fever in this age group is exceptionally low.

Patients are contagious for 24 hours after starting antibiotic treatment.
Treatment for asymptomatic GAS carriers is not recommended, nor is testing or empiric treatment of household contacts.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 4/14/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Elizabeth_Bates@ykhc.org.







Procalcitonin in Lower Respiratory Tract Infections (Adult)

For ANMC's Procalcitonin Pathway, click here.


For the supplemental resources associated with ANMC's Procalcitonin Pathway, click here.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 2/1/22. nts about this guideline, please contact Ellen_Hodges@ykhc.org.


Return to Table of Contents

Yukon-Kuskokwim HEALTH CORPORATION





69



Continue to reassess frequently while awaiting admission or transfer.

Tara_Lathrop@ykhc.org.



Clinical Guideline Sepsis Antibiotics (Adult)

Empiric Antibiotic Recommendations by Source of Infection If possible, first dose of antibiotics should be administered as a 30 minute infusion to reduce time to therapeutic concentration. **Unknown Source** Vancomycin¹ 25-30 mg/kg loading dose Gentamicin² 7 mg/kg IV Q24h. followed by 20 mg/kg Q8-12h. Piperacillin-tazobactam³ 4.5 grams IV Q8h. Consult pharmacy for max dosing. Max dose 2 grams. AND AND OR OR OR If in shock: Cefepime 2 grams IV Q8h. Levofloxacin 750 mg IV Q24h. Linezolid 600 mg IV Q12h. Community-Acquired Pneumonia Ceftriaxone 1 gram IV Q24h. If at risk for Levofloxacin 750 mg IV Q24h. (2 grams if > 80 kg.)aspiration, AND OR Metronidazole 500 mg IV Q8h. OR consider Azithromycin 500 mg PO/IV Q24h. Ampicillin-sulbactam 3 grams IV Q6h. adding: Hospital-Acquired Pneumonia or High Risk for Multi-Drug Resistant (MDR) Organisms Vancomvcin¹ 25-30 mg/kg loading dose Levofloxacin 750 mg IV Q24h. Piperacillin-tazobactam³ 4.5 grams IV Q6h. followed by 20 mg/kg Q8-12h. OR Max dose 2 grams. AND AND OR Gentamicin² 7 mg/kg IV Q24h. OR If in shock: Cefepime 2 grams IV Q8h. Consult pharmacy for max dosing. Linezolid 600 mg IV Q12h. **Meningitis** Vancomycin¹ 25-30 mg/kg loading dose If >50 Dexamethasone 10 mg IV **Ceftriaxone** Ampicillin AND followed by 20 mg/kg Q8-12h. AND years, prior to antibiotics. 2 grams IV Q12h. 2 grams IV Q6h. Max dose 2 grams. ADD Urinary Tract Infection If urological interventions or MDR risk factors, consider adding: Gentamicin² 7 mg/kg IV Q24h. AND If at risk of ESBL, ADD: **Ceftriaxone** Consult pharmacy for max dosing. Piperacillin-tazobactam³ 1 gram IV Q24h. consider <u>Meropenem</u> 3.375 grams IV Q6h. OR adding: (2 grams if > 80 kg.)500 g IV Q8h. OR Levofloxacin 750 mg IV Q24h. Cefepime 1 gram IV Q6h. Intra-abdominal or Pelvic Infection Cefepime 1 gram IV Q6h. Ciprofloxacin 400 mg IV Q12h. Piperacillin-tazobactam³ OR AND OR AND 3.375 grams IV Q6h. Metronidazole 500 mg IV Q6h. Metronidazole 500 mg IV Q8h. Skin and Soft Tissue or Necrotizing Infections Piperacillin-tazobactam³ 3.375 grams IV Q6h. AND IF PURULENT: IF NON-PURULENT: Clindamycin 900 mg IV Q8h. Vancomycin¹ 25-30 mg/kg loading dose Cefazolin 2 grams IV Q8h. lf OR followed by 20 mg/kg Q8-12h. necrotizing, OR Max dose 2 grams. Ceftriaxone 1-2 grams IV Q24h. ADD: OR Ceftriaxone 2 grams IV Q12h. Ampicillin-sulbactam 3 grams IV Q6h. AND Metronidazole 500 mg IV Q6h. Neutropenic Cancer Patients (ANC < 500) If concerned Piperacillin-tazobactam³ Vancomvcin¹ 25-30 mg/kg loading dose for HSV or Acvclovir 4.5 grams IV Q6-8h. AND followed by 20 mg/kg Q8-12h. VZV, 10 mg/kg Q8h. OR Max dose 2 grams. consider Consult pharmacy for max dosing. Cefepime 1 gram IV Q6h. adding: This guideline is designed for the general use of most patients but may Linezolid may be substituted for vancomycin in patients with relative contraindication to need to be adapted to meet the special needs of a specific patient as vancomycin for high risk for acute kidney injury. determined by the medical practitioner. Approved by MSEC 7/12/17. ² Gentamicin dosing based on ideal body weight. If comments about this guideline, please contact May substitute ampicilin-sulbactam 3 gram IV Q6h for piperacilin-tazobactam if not concerned for pseudomonas. Tara_Lathrop@ykhc.org.







Sepsis Vasoactive Medications (Adult)

Vasopressors All vasoactive medications should be infused via central line with the exception of dopamine, which can be infused via a peripheral IV at rates less than 10 mcg/ kg/minute. • Norepinephrine 8-12 mcg/min IV initial infusion rate. First-line vasopressor of choice in sepsis. Epinephrine 1-10 mcg/min initially, titrated to effect. May be added or used in place of norepinephrine to maintain adequate BP. Dopamine 2-20 mcg/kg/min. Second-line option in highly select patients as it causes more tachycardia. Phenylephrine 100-180 mcg/min IV initial infusion until stabilized. Can be used as salvage therapy for refractive hypotension associated with tachycardia. Titrate to goal of 60-200 mcg/min. (Max dose range 80-360 mcg/min.) Vasopressin 0.03-0.04 units/min. May be added to norepinephrine to increase MAP or decrease norepinephrine dose. DO NOT use as a single agent. Dobutamine 2-20 mcg/kg/min IV infusion. May be used for inoptropic support in the presence of severe myocardial dysfunction or hypoperfusion with depressed cardiac output.

Corticosteroids

Corticosteroids should NOT be administered for the treatment of sepsis in the absence of shock. Steroids are beneficial in those experiencing adrenal insufficiency in the presence of septic shot; however ACTH testing is not routinely recommended in adult patients. If hemodynamic stability is not achieved after adequate fluid resuscitation and vasopressor therapy, the use of IV hydrocortisone alone at a dose of 200 mg/day can be considered regardless of adrenal insufficiency status. Hydrocortisone should be tapered when vasopressors are no longer required.





12-18

60-100

>12 years


100-120 / 70-80

If comments about this guideline, please contact Amy_Carson-Strnad@ykhc.org.



Clinical Guideline


Sexually Transmitted Infections, Screening




No person under 16 can legally have sex with someone who is 4 or more years older.
No person under 16 can legally have sex with a person under 16 can legally have sex with a person in a position of authority over them (including a teacher, coach, or minister).

A positive STI test in a patient who fits the above scenarios should be reported to OCS, law enforcement (BPD if in Bethel or AST if in a village), and the Child Abuse Pool in RAVEN.

<u>Please note</u>: There is no lower age limit for STI testing. Any patient may be tested, regardless of age, without special consent.






• For other sites, test for reinfection in three months.




Clinical Guideline Sinusitis, Bacterial (>4 years)





Yukon-Kuskokwim


Skin and Soft Tissue Infection, page 1




to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 4/14/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Elizabeth_Bates@ykhc.org.



Skin and Soft Tissue Infection, Page 2




This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 4/14/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Elizabeth_Bates@ykhc.org.



This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 4/13/16. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Elizabeth_Roll@ykhc.org.












Tuberculosis Evaluation & Treatment (≤14 years)








Clinical Guideline UTI (3 months – 5 years)





Clinical Guideline Varicella, Suspected



For pregnant women: find out if she has a history of varicella or has received the vaccine. If not, then consult HROB to consider further treatment.

• For immunocompromised patients: refer to a provider for evaluation.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 11/2/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.






Neonatal/Pediatric Growth & Development	
Failure to Thrive in Children <24 Months	86
Late Preterm Infants, Care of	88
Newborn Early-Onset Sepsis/GBS	
Neonatal Jaundice	90
Neonatal Glucose Screening	91
Neonatal Resuscitation Summary https://yk-health.org/images/e/e4/Neonatal_resuscitation_s	



Clinical Guideline

Failure to Thrive in Children <24 Months





<u>G</u> • F

<u>G</u>

N

<u>Sc</u>

El



Failure to Thrive in Children <24 Months

<u>History</u> Use autotext "hpiFTT" to document in RAVEN.	Physical Use autotext "physFTT" to document in RA
Seneral Recurrent fevers or infections Detailed birth history Cardiovascular Sweating and/or fatigue with feeds 21 Constipation Vomiting Neurologic Developmental delay Abnormal movements Seeding Prequency, length, number per day, longest interval between feedings, night vs day? One or both breasts, softer after feeding, ± nipple shield, any pain or difficulty with latch? If pumping, how much is produced? Can you see or hear the baby swallow? Any supplementation (expressed breast milk or formula)? Does baby fall asleep at breast? Formula • Frequency, length, amount per feed and per day, longest interval between feeds, night vs day? • Does baby fall asleep at breast? Formula • Frequency, length, amount per feed and per day, longest interval between feeds, night vs day? • Type of formula and recipe • Type and size of bottle and nipple • Any supplementation (either addition to the bottle or solids)? Swallow problems • Coughing during feeding • Wet or gurgly sounds during or immediately after feeding <th>General • Cachexia, decreased subcutaneous stores, decreased • Relative macrocephaly • Lack of caregiver bonding or responsiveness to patier • Dysmorphic features or syndromic appearance HEENT • Scleral icterus • Nasal congestion or obstruction • Cleft lip or palate • Macroglossia or ankyloglossia • Micrognathia Respiratory • Stridor • Difficulty breathing, tachypnea • Abnormal breath sounds including wheezing, crackles Cardiovascular • Murmurs • Diminished or absent peripheral pulses Gi • Hepatosplenomegaly • Abdominal distension • Palpable stools Skin • Jaundice • Rashes or skin breakdown (including in diaper area) • Severe atopic dermatitis) Neurologic • Depressed mental status, inconsolability, sleepiness</th>	General • Cachexia, decreased subcutaneous stores, decreased • Relative macrocephaly • Lack of caregiver bonding or responsiveness to patier • Dysmorphic features or syndromic appearance HEENT • Scleral icterus • Nasal congestion or obstruction • Cleft lip or palate • Macroglossia or ankyloglossia • Micrognathia Respiratory • Stridor • Difficulty breathing, tachypnea • Abnormal breath sounds including wheezing, crackles Cardiovascular • Murmurs • Diminished or absent peripheral pulses Gi • Hepatosplenomegaly • Abdominal distension • Palpable stools Skin • Jaundice • Rashes or skin breakdown (including in diaper area) • Severe atopic dermatitis) Neurologic • Depressed mental status, inconsolability, sleepiness
- Frequent upper respiratory tract infections, fevers, or pneumonia Reflux	Developmental delayAbnormal movements
 Coughing, choking, gagging, or any respiratory symptoms with feeds Spitting up/vomiting 	
- Splaing up/vorniang - Arching, fussiness, or discomfort with feeds	Caloric Needs by Age
Social	If preterm, use corrected age.
- Who feeds the baby? Who lives at home? Is there a feeding schedule?	
- If bottle fed, are there concerns about obtaining enough formula?	 <37 weeks: 110 -130 kcal/kg/day 37 weeks-6 months: 108 kcal/kg/day
Elimination	• 7-12 months: 98 kcal/kg/day

- Number of wet and stool diapers per 24 hours
- Stool appearance (consistency, color, any orange/red crystal/powder, any blood or mucus)

Please see ANMC's Preterm Nutrition Resource for more information, including recipes for mixing high caloric density formula.

Initial Feeding Recommendations

Breastmilk/Formula

- Minimum Intake Recommendations:
- Term Infant: 108 kcal/kg/day = 162 mL/kg/day of 20 kcal/oz formula/breast milk - Preterm Infant: 110-130 kcal/kg/day = 177 mL/kg/day of 22 kcal/oz preterm formula
- Feeding Frequency:
- <3 months: Q3h or ≥8 feeds/day. No more than 3 hours between feeds.
- ≥3 months: Q3h during day with ≥6 feeds/day
- · Wake the baby to feed if necessary.

For Solids

- Infant must be taking at least 24 oz/day of formula or breastmilk.
- Limit any other fluids like water or juice.
- By 12 months, goal 4-6 servings of >4 tablespoons per day.

Secondary Feeding Recommendations

 If patient is able to tolerate goal feed volume, increase volume by 10% to max 180 mL/ kg/day OR increase caloric density by 2 kcal/ounce to max 24 kcal/ounce. Allow at least 24 hours to assess tolerance to any changes.

• If patient is taking solids and >9 months, consider increasing calories in solids.

• If patient is not able to consistently and safely take enough by mouth to gain weight, consider NG feeds.

es, etc.


- 12-24 months: 75-95 kcal/kg/day

Average Daily Weight Gain by Age					
Age (corrected)	Median (grams/day)				
	Girls	Boys			
2-4 weeks	29	34			
4 weeks-2 months	34	40			
2-3 months	24	27			
3-4 months	20	21			
4-5 months	16	17			
5-6 months	13	14			
6-8 months	11	11			
8-10 months	9	9			
10-12 months	8	8			
12-15 months	4-9.5	4.5-10			
15-18 months	4-9.5	4-9			
18-21 months	4-9.5	4-9			
21-24 months	3.5-9	3.5-9			


This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 3/1/22. Click here for supplemental resources for this guideline. If comments about this guideline, please contact Jennifer_Prince3@ykhc.org.



Care of Late Preterm Newborns



Approved by MSEC 8/3/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Amy_Carson-Strnad@ykhc.org.




References

 Pediatrics 2019: <u>Management of Infants</u> at Risk for Group B Streptococcal Disease

 Pediatrics 2018: <u>Management of</u> <u>Neonates Born at ≥ 35 0/7 Weeks</u>' <u>Gestation with Suspected or Proven</u> <u>Early-Onset Bacterial Sepsis</u>

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 9/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Amy_Carson-Strnad@ykhc.org.




phototherapy if patient <72 hours old or if concern for hemolysis.

If comments about this guideline, please contact Amy_Carson-Strnad@ykhc.org.



Clinical Guideline







Neonatal Resuscitation Summary

NICU (907) 212-3614 – Ask for attending neonatologist on call.

GESTATIONAL AGE (weeks)	24	26	28	30	32	34	36	38	40
ESTIMATED WEIGHT (grams)	700	900	1100	1350	1650	2100	2600	3000	3500
EQUIPMENT/SUPPLIES: NG/OG Tube - 5 French + UVC <32 weeks - 3.5 French + UVC ≥32 weeks - 5 French + UAC - 3.5 French for all gestational ages									
Laryngoscope Blade	00	00	00	0	0	0	0	0-1	0-1
ETT Size	2.5	2.5	2.5-3.0	3.0	3.0	3.0-3.5	3.5	3.5-4.0	3.5-4.0
ETT Depth lip to tip. Place at T2 above the carina.	6.5-7 cm	6.5-7 cm	7 cm	7-7.5 cm	7.5 cm	8 cm	8.5 cm	9 cm	9.5 cm
UVC insertion. <i>Place just above diaphragm. Add umbilical stump length.</i> May insert UVC 2-4 cm for emergency access.	6.5 cm	6.9 cm	7.2 cm	7.5 cm	8 cm	8.7 cm	9.4 cm	10 cm	10.8 cm
UAC insertion. <i>Add umbilical stump length.</i> High line at T6-T9 (preferred).	11.1 cm	11.7 cm	12.3 cm	13 cm	14 cm	15.3 cm	16.8 cm	18 cm	19.5 cm
UAC insertion. Low line at L3-L4. Add umbilical stump length.	7.7 cm	7.9 cm	8.1 cm	8.4 cm	8.7 cm	9.1 cm	9.6 cm	10 cm	10.5 cm
Needle decompression. See kit and protocol in neonatal code cart.	18 gauge	16 gauge	16 gauge	16 gauge	16 gauge				
VITAL SIGNS: Heart Rate 120-160 ♦ Respiratory Rate 30-60 ♦ Mean Block	od Pressure =	Gestational ag	ge in weeks						
INITIAL VENTILATOR SETTINGS									
Positive Inspiratory Pressure (PIP) cm H ₂ O	16-22	16-22	16-22	16-22	18-24	18-24	18-24	20-28	20-28
Positive End Expiratory Pressure (PEEP) cm H ₂ O	4-6	4-6	4-6	4-6	4-6	5-6	5-6	5-6	5-6
Inspiratory Time (seconds)	0.3-0.35	0.3-0.35	0.3-0.35	0.3-0.35	0.3-0.35	0.3-0.35	0.35-0.4	0.35-0.4	0.35-0.4
Respiratory Rate (breaths per minute)	30-45	30-45	30-45	30-45	20-40	20-40	20-40	20-40	20-40
Saturation Goal after 10 Minutes	88-95%	88-95%	88-95%	88-95%	88-95%	88-95%	88-95%	95-98%	95-98%
MEDICATIONS									
Epinephrine IV/IO 0.1 mg/mL 0.1-0.3 mL/kg. May repeat every 3 minutes for asystole.	0.1-0.2 mL	0.1-0.3 mL	0.1-0.3 mL	0.1-0.4 mL	0.2-0.5 mL	0.2-0.6 mL	0.3-0.8 mL	0.3-0.9 mL	0.4-1 mL
Epinephrine ET ONLY 0.1 mg/mL 1 mL/kg. <i>May repeat every 3 minutes for asystole.</i>	0.7 mL	0.9 mL	1.1 mL	1.3 mL	1.6 mL	2.1 mL	2.6 mL	3 mL	3.5 mL
Curosurf (poractant alfa 80 mg/mL) 2.5 mL/kg. Give Curosurf <26 weeks OR 26-29 weeks requiring \geq 40% FiO ₂ OR >29 weeks with CXR-proven RDS.	1.8 mL	2.2 mL	2.8 mL	3.4 mL	4 mL	5.2 mL	6.6 mL	7.6 mL	8.8 mL
FOR HYPOGLYCEMIA: Give D10 bolus 2 mL/kg IV/IO at 1 mL/min. Increase D10 maintenance fluid rate by 1 mL/hour for <2 kg or 2 mL/hour for ≥2 kg.	1.4 mL	1.8 mL	2.2 mL	2.7 mL	3.3 mL	4.2 mL	5.2 mL	6 mL	7 mL
Ampicillin (Dilute to 100 mg/mL) 50 mg/kg IV/IM	35 mg (0.35 mL)	45 mg (0.45 mL)	55 mg (0.55 mL)	68 mg (0.68 mL)	83 mg (0.83 mL)	105 mg (1.05 mL)	130 mg (1.3 mL)	150 mg (1.5 mL)	175 mg (1.75 mL)
Gentamicin (2 mg/mL) 5 mg/kg IV as one-time dose. May give IM. DO NOT USE IN VILLAGE.	3.5 mg (1.75 mL)	4.5 mg (2.25 mL)	5.5 mg (2.75 mL)	6.8 mg (3.4 mL)	8.2 mg (4.1 mL)	10.4 mg (5.2 mL)	13 mg (6.5 mL)	15 mg (7.5 mL)	17.6 mg (8.8 mL)
Volume Expanders: NS or albumin 10 mL/kg IV/IO. Give over 15-30 minutes; give faster if unstable; give slower for extreme premies.	7 mL	9 mL	11 mL	13.5 mL	16.5 mL	21 mL	26 mL	30 mL	35 mL
D10 Maintenance Fluids: <750 grams give 90-100 mL/kg/24 hours ♦ ≥750 grams give 80 mL/kg/24 hours. Goal blood glucose is 35-110 mg/dL.	3 mL/hour	3 mL/hour	3.7 mL/hour	4.5 mL/hour	5.5 mL/hour	7 mL/hour	8.7 mL/hour	10 mL/hour	12 mL/hour
Phenobarbital (130 mg/mL) 10 mg/kg IV/IO/IM/PR. May give additional 10 mg/kg dose.	7 mg (0.05 mL)	9 mg (0.07 mL)	11 mg (0.08 mL)	13.5 mg (0.1 mL)	16.5 mg (0.13 mL)	21 mg (0.16 mL)	26 mg (0.2 mL)	30 mg (0.23 mL)	35 mg (0.27 mL)

Reviewed and updated by YKHC Pediatrics, OB Nursing, and Pharmacy in conjunction with Providence Alaska Medical Center NICU Staff. MSEC approved 8/3/21.



Epinephrine 0.1 mg/mL

- This is the pre-filled syringe concentration.
- Draw up doses by inserting needle through the thick rubber stopper.

Ampicillin 100 mg/mL

Products needed:

- Ampicillin 500 mg vial
- Sterile water for injection, 10 mL vial

How to mix:

- 1. Reconstitute 500 mg vial with 4.8 mL sterile water for injection. This will result in a 100 mg/mL final concentration.
- 2. The Neonatal Resuscitation Summary (page 1) lists the total dose and volume draw up dose from vial.
- 3. Dose must be used within 1 hour of reconstitution.

Administration:

- Doses less than 500 mg can be injected via slow IV push over 3 to 5 minutes.
- Not compatible with D10W.
- Administer before gentamicin do not administer at the same time.

Gentamicin 2 mg/mL

Product needed:

• Gentamicin 100 mg/50 mL pre-mixed bag.

DO NOT ADMINISTER THE BAG - the dose will be administered via syringe pump.

The Neonatal Resuscitation Summary (page 1) lists the total dose and volume - draw up this volume from the bag and immediately dispose of the bag.


Administration:

- Administer after ampicillin do not administer at the same time.
- Administer via syringe pump over 30 minutes.
- Compatible with D10W.



Yukon-Kuskokwim HEALTH CORPORATION

Neurology	
Cerebrovascular Accident	. 95
Head Injury/Concussion (<18 years)	. 98
Seizure Evaluation (Pediatric)	. 99
Status Epilepticus Treatment (Pediatric)	100
Status Epilepticus Treatment (Adult)	101





Thrombolytic Checklist

INDICATIONS (initial yes or no)				
YES	NO			
		Less than 4.5 hours since onset of symptoms or last known normal.		
	NIHSS greater than 5 (or less than 5 with disabling symptoms).			
		Symptoms are NOT rapidly improving.		
		Symptoms are NOT due to untreated hypoglycemia (BG<50).		

ABSOLUTE CONTRAINDICATIONS (initial yes or no)

YES	NO	
		CT evidence of hemorrhage OR extensive area of hypodensity (irreversible injury).
		GI/GU bleed in the last 21 days.
		Severe, uncontrolled, hypertension >185/110.
		Current intracranial neoplasm.
		Active internal bleeding or known aortic dissection.
		Any bleeding diathesis.
		Presentation suggestive of SAH or endocarditis (not septic emboli).
		History of intracranial hemorrhage.
		Anticoagulation (warfarin or DOAC in the last 48 hours or therapeutic-dosed heparinoids).
		Any of the following in the last three months: ischemic stroke, intracranial surgery, intraspinal surgery, or serious head trauma.

RELATIVE CONTRAINDICATIONS (initial yes or no) – If any of the following relative contraindications are present, consider expert consultation prior to giving thrombinolytic and/or consider these with consent and shared decision-making.

YES	NO	
		History of GI or GU hemorrhage.
		Arterial puncture in a non-compressible site in the last seven days.
		Seizure at onset with postictal neurologic impairment.
		Major surgery in the last 14 days.
		Pregnancy.
		Onset 3-4.5 hours with NIHSS >25 (higher bleeding risk) or age >80 (higher bleeding risk).
		Untreated AVM or aneurysm.
		Systemic malignancy.
		History of arterial dissections.
		Blood glucose greater than 400 (associated with worse outcomes).

This checklist is advisory for clinical decision-making and may not be all-inclusive. Risks and benefits will need to be assessed individually.

Physician signature: _

Printed name:

____ Date and time: _

Place patient ID sticker here.



PROCEDURE CONSENT


I hereby authorize following operation or procedure	and such assistants as he/she may designate, to perform the				
· · · · · · · · · · · · · · · · · · ·					
TECHNICAL DESCRIPTION	Intravenous thrombolytic therapy for acute ischemic stroke.				
LAY DESCRIPTION	Give clot-dissolving medication through an IV to dissolve the clot which is causing a stroke.				
	has discussed with me the information briefly summarized below:				
BENEFITS	 Thrombolytic medication is a treatment that may restore blood flow to the brain. In studies, if these drugs were given less than three hours after the stroke started, 33% of patients given thrombolytic drugs had a good outcome. In patients who did not get thrombolytic drugs, 23% got better. Ten people would have to get the drug to help one person have a better outcome. If these drugs were given between three and four and a half hours after the stroke started, 35% of patients given thrombolytic drugs had a good outcome, and 30% of patients who didn't get the drug also got better. Twenty people would have to get the drug to help one person have a better outcome. Patients who receive this drug within three hours of the stroke starting have a 10% increase in chance of disability-free survival. Patients who receive this drug between three and four and a half hours from the stroke starting have a 5% increase in chance of disability-free survival. 				
	 In a large study of stroke patients, 6.8% of them had bleeding in their brain after receiving thrombolytic drugs for stroke, compared to 1.3% of those stroke patients who did not receive the drug. If we give this drug 18 times, it will probably make one person have bleeding in their brain. Among all people given this drug, 2% die from a hemorrhage. 				
RISKS OF NOT HAVING THE PROCEDURE	I • Hidder risk of developing bermanent, disabiling stroke symptoms				
ALTERNATIVE TREATMENTS	No other treatments available at this facility. Only monitoring symptoms and rehabilitation.				


Patient signature:			Witness signature:	
Printed name:	_ Date and time:		Printed name:	_ Date and time:
		1		
Physician signature:			Witness signature:	
Printed name:	_ Date and time:		Printed name:	_ Date and time:


Place patient ID sticker here.



Head Injury in Patients < 18 Years Old







Start midazolam or propofol infusion with PICU consultation.


Indications for Admission or Transfer: Status epilepticus -Cluster of seizures -Increased intracranial pressure -CNS infection Structural lesion Patient does not return to baseline mental status

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 8/3/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Jennifer_Hampton@ykhc.org.



Clinical Guideline


Status Epilepticus Treatment (Adult)






Obstetrics	
Anemia in Pregnancy	
Anti-D Immune Globulin	104
Diabetes, Gestational	105
Ectopic Pregnancy Treatment	106
First Trimester Vaginal Bleeding	107
Group B Streptococcus (Maternal)	110
HIV Screening and Prenatal Care	111
Hypertension in Pregnancy, Chronic	112
Hypertension, Gestational	113
Hypertension in Pregnant and Postpartum Patients, Severe	114
Induction of Labor	116
Intrahepatic Cholestasis of Pregnancy	117
Intrauterine Growth Restriction	118
Labor Patient in a Village	119
Molar Pregnancy	120
Oligohydramnios	121
Post-Dates Pregnancy	122
Preterm Labor: Screening and Prevention	123
Preterm Labor: Evaluation	124
Preterm Labor: Treatment	
Preterm Premature Rupture of Membranes	
Vaginal Birth after C-section	






This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 5/4/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.



This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 10/30/17. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.




Clinical Guideline Diabetes, Gestational





Clinical Guideline

Ectopic Pregnancy Treatment



This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 7/12/17. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.



1

2

heartbeat

embryo

without a yolk sac


sac with a yolk sac

yolk sac or embryo.


Yukon-Kuskokwim HEALTH CORPORATION

Clinical Guideline

First Trimester Bleeding, Ectopic Pregnancy Diagnosis, and Treatment of Non-Viable Early Pregnancy



This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 7/12/17. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.







1 Nomenclature

- Viable A pregnancy is vialble if it can potentially result in a liveborn baby.
- Nonviable A pregnancy is nonviable if it cannot possibly result in a liveborn baby. Ectopic pregnancies and failed intrauterine pregnancies are nonviable.
- Intrauterine pregnancy of uncertain viability - A woman is considered to have this if a transvaginal ultrasound shows an intrauterine gestational sac with no embryonic heartbeat and no findings of definite pregnancy failure.
- Pregnancy of unknown location A woman is considered to have this if she has a positive urine or serum pregnancy test and no intrauterine or ectopic pregnancy on transvaginal ultrasound.


2

heartbeat

embryo

without a yolk sac

sac with a yolk sac



Comments

- In a woman with a positive urine or serum pregnancy test, an intrauterine fluid collection with rounded edges containing no yolk sac is most likely a gestational sac; it is certain to ba a gestational sac if it contains a yolk sac or embryo.
- Transabdominal imaging without transvaginal scanning my be sufficient for diagnosing early pregnancy failure when an embryo whose crown-rump length is 15mm or more has no visible cardiac activity.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 7/12/17. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.






Group B Streptococcus (GBS) – Maternal

GBS Prophylaxis of the Mother at Term

Use the GBS App to determine need for prophylaxis and antibiotic of choice for GBS prevention Web version: https://www2a.cdc.gov/vaccines/m/gbs3/gbs.html or Download for your smartphone.



HIV Prenatal Screening and Care




If comments about this guideline, please contact David_Compton@ykhc.org.






Hypertension in Pregnancy, Chronic




This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. App roved by MSEC 7/12/17. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.




This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 7/12/17. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.



Clinical Guideline Hypertension in Pregnant and Post-partum Patients, Severe



This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 12/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact David_Compton@ykhc.org.




Village Management

If patient is in a village, initiate the nifedipine regimen and activate medevac to Bethel. Do not delay treatment while awaiting disposition.


If indicated, give steroids per **policy** and contact HROB for other recommendations.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 12/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact David_Compton@ykhc.org.




Bishops Score					
Score	Dilatation	Effacement	Station	Position	Consistency
0	closed	0 – 30%	-3	posterior	firm
1	1-2 cm	40 -50%	-2	mid-position	medium
2	3-4 cm	60 -70%	-1,0	anterior	soft
3	5+ cm	80+%	+1,+2		

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 12/14/16. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.






Intrauterine Growth Restriction (IUGR)



Box 1: NIPT

Non-invasive prenatal testing is a way to detect fetal chromosome abnormalities from a maternal blood draw. Our current test is InformaSeq from LabCorp.


This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 7/12/17. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.



If village delivery is anticipated, see <u>Village Deliveries (Pediatrics) Resource</u> for newborn care and preparation.

119







120



Clinical Guideline Oligohydramnios



This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 7/12/17. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.




Bishops Score					
Score	Dilatation	Effacement	Station	Position	Consistency
0	closed	0 – 30%	-3	posterior	firm
1	1-2 cm	40 -50%	-2	mid-position	medium
2	3-4 cm	60 -70%	-1,0	anterior	soft
3	5+ cm	80+%	+1,+2		

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 6/22/11. Click here to see the supplemental resources for this guideline.


If comments about this guideline, please contact Ellen_Hodges@ykhc.org.








This guideline is designed for the general use of most patients but may need to be a dapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 8/24/16. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.



There is no need to treat contractions with tocolytics in the absence of cervical change.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 7/12/17. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.




Strongly consider ketorolac. Consider transfer to Anchorage.

This guideline is designed for the general use of most patients but may need to be a dapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 7/12/17. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.




126



This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 7/26/17. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.



Vaginal Birth after Caesarean Section



This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 3/1/22. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.



Yukon-Kuskokwim **HEALTH CORPORATION**

Preventative Health Care Amoxicillin Allergy Trials (Pediatric)...... 129 Aspirin for Adults >40 Without Known Cardiovascular Disease......130 Lead Evaluation (Pediatric)......132 Sports Clearance for Pediatric Patients with History of COVID-19...... 134 Osteoporosis Screening and Treatment...... 135



Clinical Guideline

Amoxicillin Allergy Trials (Pediatric)



 Only 4-9% of those...labeled [penicillin-allergic] are currently allergic. It is important to identify those who are not allergic, because children mislabeled as penicillin-allergic have more medical visits, receive more antibiotic prescriptions, and have longer hospitalizations with more antibiotic-related complications.¹

• Up to 10% of children develop rashes while receiving antibiotics. Most are diagnosed...as allergic to the implicated antibiotic, and most continue to avoid the suspect antibiotic in favor of alternatives, which may be less effective, more toxic, and more expensive.²

• Do not label a patient as allergic to penicillin/ amoxicillin unless he or she has true hives, anaphylaxis, or a life-threatening reaction. Please include photos of rashes in RAVEN.

Children labelled as allergic to penicillin/amoxicillin often carry that label for the rest of their lives.
Please consult a pediatrician with any questions.

Anaphylaxis

• Acute onset – several minutes to hours from exposure.

 Generalized hives, pruritis or flushing, swelling of lips/tongue/uvula, and at least one of the following:

Dyspnea, bronchospasm, stridor Hypotension

Evidence of hypoperfusion of endorgans

Persistent crampy abdominal pain, and/or vomiting or diarrhea

Hives vs Viral Rash

• True hives are raised, <u>itchy</u>, larger than dime-sized, come and go, move around the body, and change shape and size. True hives are uncomfortable. Ask if the rash bothered the child.


 Keep in mind that many parents refer to any rash as "hives." Get a description every time.

• A viral exanthem is typically diffuse, fine, pinpoint red dots and can be dense, coalesced, larger raised lesions. The rash typically covers the face and chest but can cover the whole body. The rash typically worsens and takes days to clear.

References

1. Kelso JM. "Provocation challenges to evaluate amoxicilin allergy in children." JAMA Pediatrics 2016;170(6):e160282.

 Mill C, et al. "Assessing the diagnostic properties of a graded oral provocation challenge for the diagnosis of immediate and nonimmediate reactions to amoxicillin in children." JAMA Pediatrics. 2016;17(6):e160033.



Amoxicillin Trial Procedure²

Use AMB Amoxicillin Trial Power Plan.

1. Obtain VS. Perform physical exam, including lung exam. Have appropriate dose of EpiPen or epinephrine. Epinephrine (1 mg/mL): 0.01 mg/kg (or 0.01 mL/kg) IM Q5-15 minutes. Per AAP recommendations:

- 7.5-25 kg: use EpiPen Jr (0.15 mg)
- ≥ 25 kg: use EpiPen (0.3 mg)
- 2. Calculate weight-based dose of amoxicillin. Give patient 10% of that dose.
- 3. Place patient in nearby room and instruct caregiver to notify staff of any changes in status.
- 4. If no reaction by 20 minutes, give patient remaining 90% of weight-based dose of amoxicillin.

5. Observe another 60 minutes. If no reaction, check VS and physical exam. If all stable, discharge home with regular course of drug.

6. Give patient and family amoxicillin trial education sheet.

7. Update allergy alert in RAVEN. Click the allergy in the banner. Right click over the drug name and choose "cancel." On the "reason" drop-down menu, choose "OK on Retrial."

Notes:

• If patient is on a beta-blocker, stop this for 24 hours prior to procedure, if possible. Beta-blockers can interfere with treatment for anaphylaxis, if it occurs.


• Ensure that patients with asthma have optimal control prior to this procedure.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 8/3/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.



Π

Yukon-Kuskokwim HEALTH CORPORATION



Notes


Aspirin produces significant reductions in mortality amongst survivors of cardiovascular disease, but its role in the primary prevention of cardiovascular disease amongst healthy adults is less clear.

See <u>table under "Possible Benefits"</u> for summary of RCT data for low dose aspirin in the primary prevention of cardiovascular disease.




Clinical Breast Exam Screening Recommendations:1. Breast self-examination:at provider's discretion2. Clinical breast examination:at provider's discretion3. Mammography:start age 45

screen every 2 years end screening at age 70, based on health status



This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 6/22/11. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.



Common Sources of Lead in Alaska

- Mining lead, zinc, silver, or gold ore
- Lead paint in homes or buildings built before 1978
- Firearms and ammunition
- Shooting ranges
- · Game meat shot with lead ammunition
- Fishing weights
- Leaded aviation gas
- Marine paint
- Soldering, welding, or craft-making
- Pica or "mouthing" (eating dirt)
- Imported household objects
- Lead or brass pipes/faucets
- Batteries and automobile repair sites

**To consult YK Office of Environmental Health (OEH), call 543-6420 with patient's name and DOB, lead levels, and parent's contact information.

OEH can review environmental risk factors with family and offer a home visit if appropriate.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 3/1/22. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Justin_Willis@ykhc.org.



Clinical Guideline

Primary Care for Ex-Premies - Checklist

Initial Visit

Review NICU/Nursery course and summarize highlights in note. Update Problem List. Make patient CPP.

 Enter birth weight and gestational age so that RAVEN Growth Chart will correct for gestational age. (Go to Growth Chart \rightarrow Enter New \rightarrow Measurement \rightarrow Preterm Growth Chart: Change date to DOB, enter gestational age at birth, and enter birth weight.)

Check height and weight. Do not discharge to village if not having appropriate weight gain (at least 25 grams per day for 4-5 consecutive days), temperature <97.7, or rising bilirubin level.

□ Check bilirubin level if appearing jaundiced.

 Ensure infant is receiving fortified formula (ie Neosure) if discharged from the NICU on it. Infant should remain on this formula until 6 months corrected gestational age.

□ Place order: "Refer to Family, Infant, Toddler Program."

□ Place order: "Refer to Audiology Internal." In comments, type, "Premature infant: needs evaluation by 9 months corrected gestational age."

□ If born <34 weeks, place order: "Refer to Child Family Developmental Services External", CFDS Sub-Specialty drop down "NICU Graduate Clinic."

□ Place referrals for any subspecialists per NICU/nursery discharge summary.

□ If Hgb level <9.5 g/dL at discharge, repeat hemoglobin level 2 weeks after discharge. If still <9.5 g/dL, repeat 2 months post-discharge.

Uvrite Vitamin D prescription with 11 refills and ensure receiving 800 IU Vitamin D supplementation. (Polyvi-sol with iron has 400 IU of Vitamin D per drop.)

Urite iron prescription with 11 refills and ensure receiving iron supplementation (Poly-vi-sol or iron polysaccharide). Needs 2 mg/kg iron supplementation for first year of life. (Note: Poly-vi-sol with iron contains 11 mg/mL of iron.)

All Subsequent Visits until Child is 24 Months Old

Review and update Problem List.

Assess growth based on corrected gestational age. Consult pediatrics if: there is a need to increase/decrease feeding calories, head circumference growth >1.25 cm/week, or infant is crossing major percentile lines.

Review feeding, sleep, and development in detail.

Check on FIT involvement. If family has not been contacted by FIT, reach out to Peds Wards on Duty, who will contact the FIT liaison.

Give all vaccines per routine schedule based on chronologic age.

Administer ASQ at <u>9 months</u>, <u>18 months</u>, and <u>24 months</u> chronologic age.

Administer MCHAT-R at 18 months and 24 months chronologic age.

□ Ensure specialty appointments/referrals have been made.

If on caffeine, alter dose based on <u>Caffeine Protocol</u>, Post-NICU Discharge Resource.

□ If diagnosis of Bronchopulmonary Dysplasia or Chronic Lung Disease of Prematurity, check blood pressure at each visit. For normal neonatal and infant BPs, see this page, table 1 and figures 1A and 1B.

□ If infant qualified for Synagis, ensure monthly doses are given during RSV season until course is complete. Ensure patient is scheduled for these visits. Check Problem List for when next dose is due and how many doses will complete infant's course. If concerns or questions, email YKHCSynagis@ykhc.org.

□ Ensure receiving Vitamin D 800 IU supplementation (Poly-vi-sol with iron has 400 IU of Vitamin D per drop).

□ Ensure receiving iron supplementation (Poly-vi-sol or iron polysaccharide). Needs 2 mg/kg iron supplementation for first year of life. (Note: Poly-vi-sol with iron contains 11 mg/mL of iron.)

Documentation: Use the autotext "...pednicugrad" for a summary of this checklist for charting purposes.


To consult the pediatrician on call, send a
message through Tiger Connect to Peds
Wards on Duty.

General Information
 Soy milk formulas should not be given to preterm infants. Physiologic reflux is more common in preterm infants. There is no evidence to support the use of gastric acidity inhibitors. H₂ blockers and PPIs are associated with gastroenteritis, pneumonia, and bone fractures. Catch up growth of premature infants occurs for head first (3-8 months), then weight, then length. Recommend every member of the household is up to date on Tdap, COVID, and seasonal influenza vaccines to protect these high-risk infants.
Criteria for Referral to Child Family Developmental Services (CEDS) Birth to Three High Risk Clinic This is a specialty clinic in Anchorage that follows high-risk infants. • Birth weight (BW) <1500 grams. • Gestational age <34 weeks. • Cardiorespiratory depression at birth • Apgar score <5 at 5 minutes • Prolonged hypoxia, acidemia, hypoglycemia, or hypotension requiring pressors. • Persistent apnea requiring medication. • Oxygen support for >28 days and X- ray findings consistent with chronic lung disease. • Extracorporeal membrane oxygenation (ECMO) • Persistent pulmonary hypertension of the newborn (PPHN) • Seizure activity • Intracranial pathology, including intracranial pa

Please see the Care of Late Preterm Newborns guideline for information about late preterm babies who were cared for at YKDRH and were not admitted to a NICU.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 11/2/21.

If comments about this guideline, please contact Justin_Willis@ykhc.org.



Symptom Severity Classification for this Guideline

Mild: no fever, <3 days of symptoms
Moderate: prolonged fevers and bedrest, hospitalization not required, no abnormal cardiac testing throughout course

• Severe: hospitalized, abnormal cardiac testing, or MIS-C

Note: Providers may use their clinical judgment and perform an ECG if cardiac concerns not addressed by this guideline.

Phone Numbers

Seattle Children's Pediatric Cardiology of Alaska (located in Anchorage): • Phone: (907) 339-1945 • Fax: (907) 339-1994

This guideline is designed for the general use of most patients but may need to be a dapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC ad hoc committee for COVID-related guidelines 8/24/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.



Clinical Guideline Osteoporosis Screening

Yes


Yes

Obtain screening radiology test:

Quantitative CT (Bethel)

DXA (Anchorage)

Yes




Recommend preventive measures: Regular weight-bearing exercise. Adequate calcium and vitamin D intake. Avoid tobacco and alcohol.

No

Recon	nmended	Calcium Intake
Age	<u>Sex</u>	RDA mg/day
9-18	M+F	1300
19-50	M+F	1000
51-70	М	1000
51-70	F	1200
>71	M+F	1200

Recommended Vitamin D Intake				
Age	<u>Sex</u>	<u>RDA IU/day</u>		
14-70	M+F	600		
>71	M+F	600		

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 9/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact David_Compton@ykhc.org.



Return to Table of Contents.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 9/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact David_Compton@ykhc.org.



Psychiatry	
Alcohol Hangover/Withdrawal	138
Attention Deficit Hyperactivity Disorder (Pediatric)	
Intoxicated Patient	140
Involuntary Psychiatric Admissions	141

Return to Table of Contents




ma)

Yukon-Kuskokwim HEALTH CORPORATION


Clinical Guideline

Alcohol Hangover/Withdrawal





Attention Deficit Hyperactivity Disorder (Pediatric)





1. Scan completed Vanderbilt forms into MultiMedia Manager under "Continuity of Care."


To refer to Dr. Jackman: use "Refer to Peds Psychiatry Internal" order. Dr. Jackman may be contacted at (907) 230-3765 or jackman@alaska.net.
 To refer to CFDS or other private psychologist: use "Refer to Other External" order and send a message to the case manager to process the referral.

4. E-prescribe three separate 30 day prescriptions after checking Alaska PDMP. Include the month the medicine is to be filled in the comments or special

instructions section.







combative. 1:1 monitoring is required due to ligature risk. Consider ET CO₂ monitoring.

If comments about this guideline, please contact Travis_Nelson@ykhc.org or Kaia_Pearson@ykhc.org.



// III

• 0 •


Yukon-Kuskokwim HEALTH CORPORATION

Trauma/Injury/Ingestion	
Acetaminophen Overdose (Adult and Pediatric)	143
Burns (Adult and Pediatric)	144
Frostbite (Adult and Pediatric)	145
Head Injury/Concussion (<18 years)	146
Rabies	147
Strangulation	148



Clinical Guideline

Acetaminophen Overdose (Adult and Pediatric)




143


Return to Table of Contents.

Yukon-Kuskokwim HEALTH CORPORATION

Clinical Guideline Burns (Adult and Pediatric)








145



Yukon-Kuskokwim

Head Injury in Patients < 18 Years Old





Day 7 dose: Given in village from HAND CARRY.


Day 14 dose: Given in village from HAND CARRY.

Yukon-Kuskokwim

Clinical Guideline

147

Rabies



to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 12/2/20. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Abigail_Klager@ykhc.org.



Strangulation

Goals Patient presents with concern for strangulation 1. Evaluate carotid and vertebral arteries for injuries. 2. Evaluate bony/cartilaginous and neck soft Are ANY of the following present? tissue structures. 3. Evaluate brain for anoxic injury. Airway: subcutaneous emphysema (can be a sign of tracheal or laryngeal rupture) Neurological: loss of consciousness, seizures, mental status changes, amnesia, cortical blindness, movement disorders, stroke-like symptoms Note: Life-threatening injuries can • HEENT: be present up to one year after - Visual changes: spots, flashing lights, tunnel vision, etc. - Facial, intra-oral, or conjunctival petechial hemorrhage strangulation event. - Odynophagia Neck: - Ligature mark, neck contusion, soft tissue injury, swelling, carotid tenderness, etc. Helpful Links - Dysphonia/aphonia, hematoma, laryngeal fracture, recurrent laryngeal nerve injury Bladder or bowel incontinence S/Sx strangulation in adults and children Pulmonary: dyspnea, phrenic nerve injury Physiological consequences timeline •No to ALL--Yes to ANY-Rule Out Life-Threatening Injuries • If GFR ≥30: CT angio of carotid/vertebral arteries. This is the gold standard for evaluation of vessels and bony/ No injury Is there reliable home monitoring How recent was ≥ 48 hours cartilaginous structures but is not very sensitive for soft identified AND a safe place to go to? event? ago tissue trauma. If GFR <30: non-contrast CT of neck. This study is less <48 hours ago sensitive than CT angio for vessel injury but gives good visualization of bony and cartilaginous structures. Observe in ED or admit to Discharge home with Consider inpatient until 48 hours post-event discharge to TWC. detailed instructions to return Injury identified based on severity of symptoms. • May call TWC to ED if any neurological ¥ signs/symptoms, dyspnea, Crisis Line (543-• Consult trauma surgery and plan to transfer. dysphonia, odynophagia 3456) for Consider ENT consult for laryngeal trauma assistance with dysphagia, or voice changes with dysphonia. occur or worsen. safe shelter. Give custom Strangulation Also may call SART on call at Patient Education handout. 545-4238 for

Tundra Women's Coalition (TWC)

further assistance.

- Crisis Line: 543-3456
- Main office: 543-3444
- On-call advocate: 545-4328

Services Provided by TWC

- Emergency shelter
- Hospital accompaniment
- Information about community resources
- Legal advocacy
- Violent crime compensation
- Funds for emergency air or cab transportation

If patient would like to report incident:

- If occurred in a village: Alaska State Troopers 543-2294
- If occurred in Bethel: Bethel Police Department 543-3781

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 11/2/21. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Jennifer_Prince3@ykhc.org.

Yukon-Kuskokwim

Neonatal Reference	
Neopuff Set-Up Guide	150
Pneumothorax Evacuation Protocol	152
Surfactant Administration Protocol	153
Village Deliveries	154




Attach the oxygen tubing to a 15 L flow meter.


Set the flow meter to **10** L.

Occlude both the mask and the hole. Set the PIP: Turn the knob labeled Peak Inspiratory Pressure until the arrow on the dial points to 20.

Occlude only the mask. <u>Set the PEEP</u>: Turn the PEEP knob until the arrow on the dial points to **5**.




This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.




















Yukon-Kuskokwim





- Occlude both the mask and the hole.
- <u>Set the PIP</u>: Turn the knob labeled Airway Pressure Relief until the arrow on the dial points to **20**.





- Occlude only the mask.
- <u>Set the PEEP</u>: Turn the PEEP knob until the arrow on the dial points to **5**.





Troubleshooting: If you cannot achieve the desired pressures, try changing the liters on the flow meter.

This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.



Neonatal Pneumothorax Evacuation Protocol

Coming soon...

This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.





Surfactant Administration Protocol

Indications for Curosurf[®]

- GA<26 weeks.
- GA 26-29 weeks with supplemental
- oxygen requirement ≥ 40%.

GA>29 weeks with CXR-proven RDS.

Curosurf[®] Storage

- Curosurf[®] is stored at 36-46°F.
- If warmed and not opened or used, may be
- returned to refrigerated storage one time. • Curosurf[®] is located in the OB medication refrigerator. If going on a medevac, ask the nurses to get the Curosurf[®]. It can be stored in a pink thermal bag that is kept next to it in the refrigerator.

Reference:

See this <u>YouTube video</u> for a demonstration of the Y catheter.

• Warm to room temperature and gently invert. Do not shake.

Choose Curosurf[®] dose using the <u>Neonatal Resuscitation Summary</u> using estimated gestational age. If

Preparation of Curosurf®

weight is known, calculate dose to be 2.5 mL/kg.

Draw up total Curosurf[®] dose using a 20 gauge or larger needle.

Preparation of Equipment and Patient

- Prior to intubation, if possible, check the ETT cap and make sure it comes on and off easily.
- Make sure you have the correct size Y cap for the ETT size.
- Check fit of Y cap on ETT. Attach catheter and feed it down the tube until it is ½ cm past the tip. Look for the number or color that will tell you the depth of the catheter at this point.
- Intubate patient with ETT cap on tube.
- Verify placement and secure tube.

Administration of Curosurf®

- Infant should be supine.
- Disconnect Neopuff, bag, or ventilator.
- Remove ETT cap and replace with Y cap. (If ETT cap is stuck, cut the tube as high as possible and then place the Y cap.)
- Attach the Neopuff or bag to the larger port on the Y cap.
 - Attach the catheter to the smaller port on the Y cap and advance it until it is at the desired depth.
 - Inject the syringe of Curosurf® through the catheter.
 - Pull the catheter all the way out but leave attached.
 - Bag the baby at a rate of 40-60 breaths/minute for one minute.
 - Allow the baby to recover.
 - Remove the Y cap and replace the ETT cap.
 - Resume ventilation.
 - Do not suction for one hour after administration unless required for obstruction.
 - Remember to adjust pressure on Neopuff as lung compliance improves.


This resource is designed for the general use of most patients but may need to be a dapted to meet the special needs of a specific patient as determined by the medical practitioner. Click here to see the supplemental resources for this resource. If comments about this resource, please contact Leslie_Herrmann@ykhc.org.



Return to Table of Contents. Yukon-Kuskokwim HEALTH CORPORATION

n

Village Deliveries (Pediatrics)









Obstetrics Protocols/Reference	
ntepartum Patient1	56
Prenatal Care 1	57







n

Yukon-Kuskokwim HEALTH CORPORATION

BASICS

- Review the chart EVERY visit for incomplete lab or other required testing.
- Review the Problem List EVERY visit for needed testing or intervention items.
- Patient should see a Bethel provider or CHA/P monthly from first visit to 32 weeks.
- Patient should see a Bethel provider or CHA/P every two weeks after 32 weeks and then weekly at 36 weeks.
- If there is any question of EDC, see guideline or refer to HROB meeting for decision.

First Prenatal

NURSING/CASE MANAGER

- Order First Trimester Transvaginal OB Ultrasound (>6 weeks) for dating.
 Patient to initiate paperwork:
 - Residential Information Sheet.
 - Pregnancy Verification Sheet use LMP if no EDC from ultrasound.
 - · Quad screen consent form.
 - FAS & Drug Assessment Screening questionnaire.
 - 36 Week BIB/Medevac Policy.
- Review TB screening status patient MUST HAVE a negative Quantiferon or PPD prior to 36 weeks to stay at Prematernal Home. Place PPD if needed.
 Labs: urinalysis, urine culture, blood type and screen, HBsAg, Hepatitis C antibody, CBC, Rubella titer, HIV testing, treponemal testing, HgA1c, 25-OH vitamin D.
- Set up room for pelvic to do PAP (only do a PAP if it is due), GC/CT and trichomonas (with verbal consent).
- Routine patient handouts: WIC handout.

PROVIDER

- Prenatal H&P and Prenatal Education.
- Chart review.
- Offer flu vaccine October through the end of the flu season.
- Discuss and sign BIB/Medevac Policy contract.
- Update the Problem List and include EDC and gravida/para in one problem.
- Refer to HROB meeting if needed.
- Ask about S/Sx of IHCP; if present, add bile acids and LFTs to lab draw.

PATIENT

- · Go to the Medicaid office to file for Medicaid.
- Go to the WIC office to file for WIC.

15-21 Weeks

If desired, quad screen must be drawn between 15 and 21 weeks gestation.
Review TB status.

20 Weeks

- Ultrasound to screen for anomalies: US OB anatomy and cervical length.
 - Only one is needed no matter where it is done.
 - Aim for 20 weeks.
 - $^{\circ}$ If anatomy is incomplete, order US OB follow-up for the next visit to complete the anatomy exam.

24-28 Weeks

NURSING

- Labs: GST, CBC.
- Tdap after 24 weeks.
- GST 50 g:
 - If result >140 mg/dL, schedule 2 hour GTT ASAP.
- If the result >179, no GTT; refer directly to diabetes education.
- Attempt to keep the patient until the results of the GST are back.
- Review TB status. Draw Quantiferon if failed to have PPD read.

PROVIDER

- After 28 weeks, ask about preeclampsia symptoms.
- After 24 weeks, ask about preterm labor symptoms and IHCP symptoms.
 Back pain.
 - Sudden increase in vaginal discharge.
 - Pelvic pressure.
 - · Cramps/contractions.
- · Educate patient on fetal movement count.

36 Weeks/BIB Date

• Labs: CBC, treponemal testing, HIV testing, GBS culture, GC/CT and trichomonas.


- Review TB status. Draw Quantiferon if status unknown.
- Schedule appointments to be seen each week by Bethel provider through
 41 weeks.
- Complete Prematernal Home/Medical Clearance paperwork.
- Ask about any symptoms of:
 - Rupture of membranes.
 - Preeclampsia.
 - Labor.
 - Itching.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 7/6/21. Click here to see the supplemental resources for this protocol.

lick here to see the supplemental resources for this protocol. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.



Outpatient Protocols/Reference	
Chronic Pain: Narcotic Treatment Eligibility	159
Chronic Pain, Follow-up	160
Colon Cancer Screening	
Contraception: Quick Start	162
Pre-anesthesia Testing	



injections, capsaicin cream, lidocaine patch/cream, yoga, meditation 2. Neuropathic Pain:

Suggested treatments: NSAIDs, antidepressants (first-line TCAs, duloxetine), gabapentin


Management for specific conditions:

- · Nerve compression: EMG, MRI, referral to surgeon
- Nerve damage: EMG
- Nerve traction: EMG, PT, yoga, meditation
- · Migraine: sumatriptan, rizatriptan, beta-blockers, etc.
- Reflex sympathetic dystrophy: lidocaine patch
- 3. Idiopathic Pain: examples include fibromyalgia

Suggested treatments: exercise, antidepressants (including duloxetine), yoga, meditation, sleep hygiene

This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 2/1/22.


If comments about this guideline, please contact Heidi_Salisbury@ykhc.org.




For terminal cancer patients (with life expectancy less than or equal to 6 months) who have previously demonstrated good compliance with Chronic Medication agreement, documentation of titration for pain control as appropriate is acceptable without requiring new agreement. Continue to monitor for achievement of goals/behaviors of concern.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 2/1/22. If comments about this guideline, please contact Heidi_Salisbury@ykhc.org.








This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 12/14/16. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.





This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 3/25/13. If comments about this guideline, please contact Ellen_Hodges@ykhc.org.



n

Yukon-Kuskokwim HEALTH CORPORATION

Treatment Protocol

Pre-Anesthesia Management

Age	Hb/Hct	Coags	Lytes	BUN/Cr	Glucose	LFTs	EKG	CXR	T&S
0 – 59 years	9 years No routine testing needed in this age group.								
60 – 74 years							X		
75 – 99 years	X		X	X	X		X		
Disease	Hb/Hct	Coags	Lytes	BUN/Cr	Glucose	LFTs	EKG	CXR	T&S

Disease	пр/пст	Coags	Lytes	DUN/Cr	Giucose	LFIS	ENG	CAR	103
Hypertension			Х				Х		
Card – moderate	X		Х	X			Х		
Card – severe	Х		Х	Х			Х	Х	
Pulm – mild									
Pulm – severe	X						Х	X	
Smoker > 20 years	X								
Malignancy	X								
Lymphoma								X	
Hepatic	X	X	Х			X			
Renal	X	X	Х	X					
Bleeding	X (CBC)	X							
Diabetes			Х	Х	Х		Х		
Expected blood loss	Х								Х

Medication	Hb/Hct	Coags	Lytes	BUN/Cr	Glucose	LFTs	EKG	CXR	T&S
Diuretic			Х	Х					
Antihypertensive			x	x			Х		
Cardiac medication			Х	Х			Х		
Steroid			X		X				
Anticoagulant	Х	Х							

<u>Other</u>

Urine hCG: obtain within 48 hours of surgery in women of childbearing age (13-50).

Drug Levels: draw level on all patients on digoxin or phenytoin.

CXR: obtain if recent change in sputum quality or color, pneumonia in past three months, chronic home oxygen use, planned intrahoracic surgery, or if exam reveals rales, rhonchi, or wheezes.

Surgical Risk Screening Protocol Orders

1. Patients who are not to be scheduled at YKHC:

- a. Patients with BMI > 45 (up to BMI of 45 is acceptable if no significant unstable CV, respiratory, or endocrine pathology is present).
- b. Obstructive sleep apnea perioperative risk score of 5 or 6.

2. Preventative antibiotic therapy will be administered within one hour prior to skin incision per protocol pre-operatively based on procedure type and patient's allergies unless otherwise ordered by physician.

3. DVT/VTE prevention methods will be implemented using SCIP Mechanical Prophylaxis Protocol unless ocntraindicated or otherwise documented in orders by physician.

Diabetes Management

- 1. Discontinue all oral agents the evening prior to surgery except Metformin, which can be taken the evening prior to surgery but not the day of surgery.
- 2. Discontinue insulin after midnight for AM surgeries.
- 3. Take half usual dose of insulin the morning of surgery if surgery is scheduled to start at noon or later.
- 4. Take full dose of Lantus insulin up to time of surgery.
- 5. Consume apple or cranberry juice up to two hours prior to arrival to surgery if insulin was given.
- 6. For insulin pumps, set to basal rate and continue throughout pre-operative period.
- 7. Upon arrival to Holding Area, obtain glucose level. Anesthesia will treat results.





NPO Guidelines

The preoperative nurse will instruct all patients to be NPO after midnight and to follow the surgeon's instructions if they differ from this. The surgeon who gives different instructions will be responsible for thorough patient instruction of anything other than these guidelines.

1. All patients are equal with regard to NPO guidelines (eg gastric emptying time, obesity).

2. Clear liquids may be consumed up to two hours prior to scheduled arrival time.

3. Clear liquids are water, black coffee, and beverages not cloudy that can be seen through. Sugar and artificial sweeteners are acceptable. All broths are NOT acceptable.

4. Patient may brush his/her teeth but should not swallow toothpaste.

5. Gum and candy of any type are not allowed.

6. All patients will be allowed to eat a full, regular diet (solids) up to eight hours prior to surgery. Patients going to the OR at 0730 who were NPO after midnight are considered to meet this standard.

7. Infants up to 24 months of age will be allowed breast milk up to four hours prior to the arrival to the hospital. Infant formula is considered a solid.

	Estimated Energy Requirements for Various Activities, Based on Duke Activity Status Index*					
1 MET	Can you					
		take care of yourself?				
		eat, dress, or use the toilet?*				
		walk indoors around the house?				
		walk one or two blocks on level ground at 2-3 mph (3.2-4.8 kph)?				
< 4 METs	Can you					
		do light work around the house, such as dusting or washing dishes?				
≥ 4 METs	Can you					
		climb a flight of stairs or walk up a hill?				
		walk on level ground at 4 mph (6.4 kph)?				
		run a short distance?				
		do heavy work around the house, such as scrubbing floors or lifting or moving furniture?				
		participate in moderate recreational activities, such as golf, bowling, dancing, doubles tennis, or throwing a baseball or football?				
≥ 10 METs	Can you					
		participate in strenuous sports, such as swimming, singles tennis, football, basketball, or skiing?				
* MET = metabolic equi	valent					
Adapted from J AM Co	I Cardiol, with pe	ermission from Elsevier.				

0



Pediatric Protocols/Reference	
Caffeine Protocol, Post-NICU Discharge	166
Care Conference Checklist	167
Dexamethasone in Meningitis	168
Diabetic Ketoacidosis Management	169
Endocrine Emergencies	172
Endocrine Referrals/Labs and Follow-up Recommendations	175
Hip Exam and Surveillance in Infants	178
Induced Sputum Collection	179
mPEWS Protocol for Pediatric Patients	180
Nutritional Supplements, Documentation Requirements	181
Orthotics, Documentation Requirements	182
Suspected Septic Arthritis and Osteomyelitis	183





PAMC/YKHC Post-NICU Caffeine Protocol

IF ANY CONCERN FOR APNEA, please consult a pediatrician immediately to determine need for further evaluation, transfer, medevac, etc.

Recommendations on Management of Caffeine After NICU Discharge

• Recommended dose of caffeine is 12 mg/kg PO daily.

• Patient should be seen in Bethel by a pediatric provider within one week of returning to the region.

• Dose should be weight-adjusted every 1-2 weeks. This can occur in outpatient clinic with a pediatric provider or a pediatric consult, in an SRC with a pediatric consult, or in a village by RMT to Chronic Peds.

Stop the caffeine when the baby is 42 weeks corrected gestational age.
Discontinuation of caffeine may be delayed for another week so as not to coincide with immunizations, recent URI, or planned anesthesia (as all of these events can cause re-emergence of intermittent hypoxia with periodic breathing).

<u>Note</u>

When a baby is discharged from the NICU on caffeine, update the Problem List with the plan, including the target dose, how often to weight-adjust, and the expected end date (when 42 weeks corrected gestational age will be).

Rationale

• In the past, premature infants were given caffeine until about 34 weeks postmenstrual age. Some needed caffeine past this point and went home on caffeine and an apnea monitor.

• Recent studies have shown that many preterm infants who have been taken off caffeine will go on to have intermittent hypoxia and subclinical apnea and bradycardia events after discharge from the hospital.

• Evidence is also building that prolonged use of caffeine results in better neurodevelopmental outcomes.

• As of January 2019, caffeine has been continued in preterm infants after discharge from the PAMC NICU.

• The PAMC NICU stopped the routine use of apnea monitors for babies discharged on caffeine due to sub-optimal monitor technology and frequent frustration among parents and providers. They prefer to emphasize the importance of giving caffeine rather than use of apnea monitors.

<u>Source</u>

Adapted from letter from Alaska Neonatology Associates, Inc., Pediatrix Medical Group, an affiliate of MEDNAX. 1/10/2019 Providence Alaska Medical Center (PAMC) Neonatal Intensive Care Unit (NICU)

This resource is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Last reviewed 12/2/20.

166

If comments about this resource, please contact $\mbox{Leslie}_\mbox{Herrmann}\ensuremath{@ykhc.org}.$



Clinical Resource Checklist for Complex Pediatric Patients Returning to YKHC Region

Has YKHC pediatric group been briefed and asked for feedback on concerns or issues?	□ N/A
Prior to patient returning, has care conference been scheduled with 1-2 pediatricians to represent group/consensus recommendations? Other key participants include: case managers, SRC providers, health aides, and family members.	□ N/A
Where will primary care occur – village, SRC, Bethel, or Anchorage?	□ N/A
□ Does home have electricity, running water, and a refrigerator?	□ N/A
□ Is there a back-up plan in place if electricity goes down?	□ N/A
□ Have family/caregivers received CPR training?	□ N/A
Does the family have needed emergency equipment? Ex: ambu bag (if no CHA available), suction, pulse-oximeter, oxygen, etc. Have they received training on how to use this equipment?	□ N/A
Does the family have needed supplies: medications, beds, commodes, syringes, dressings, wheelchair, lotions, etc.?	□ N/A
If the patient is at risk for seizures, has the family received Diastat or intranasal midazolam and received the appropriate training?	□ N/A
□ If the patient has a G-tube, are the caregivers comfortable replacing it? Do they have emergency supplies, including an extra G- ube and Foley catheters in the same French size and smaller sizes?	□ N/A
If the patient has a port, are the caregivers comfortable accessing it? Have they received the appropriate training? Do they have all the supplies needed to access it?	□ N/A
□ Has an Informed Consent to Return to Village been customized for this patient and approved by Risk Management (contact is Linda Weisweaver as of 11/2019)? [See Peds Folder → Informed Consent to Return to Village for template.]	□ N/A
Have the caregivers completed the Informed Consent to Return to Village?	□ N/A
If patient is returning to the village against medical advice, have Risk Management, Clinical Director, and appropriate administrators been made aware?	□ N/A
□ If the patient is DNR/DNI/Comfort Care, have the Expected Home Death Forms been completed? Has the MOST Form been completed? Does family have enough medications needed for comfort care?	□ N/A
Have all current and anticipated prescriptions with refills been ordered on the YKHC RAVEN Medication List?	□ N/A
□ Has the YKHC RAVEN Problem List been updated with care plans, follow-up needs, therapeutic parameters, etc.?	□ N/A
□ Has a clinic appointment been scheduled to establish care at YKHC?	□ N/A
□ Have the health aides been notified of the complex needs of this patient?	□ N/A
□ Have the nearest SRC providers been notified of the complex needs of this patient?	□ N/A
After the care conference: has a detailed note been placed in the chart summarizing the care conference? Has this note been sent by email to the pediatric group, case managers, and SRC providers?	□ N/A
□ Has family referral to YKHC BH been offered?	□ N/A
□ Have VTC appointments been set up for patient and family?	□ N/A

This resource is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. If comments about this resource, please contact Leslie_Herrmann@ykhc.org.





Clinical Resource

Dexamethasone in Meningitis

The following is adapted from the "<u>ANMC</u> <u>Pediatrics Statement on Dexamethasone</u> <u>and Hearing Screening in Meningitis</u>," dated 2/4/20.

Haemophilus influenzae type A

In recent years, *Haemophilus influenzae* type A (HiA) meningitis has been more common than other causes of bacterial meningitis in children admitted to ANMC. Many of these children have been transferred from YKHC. See this <u>State Epidemiology Bulletin</u> for information about Alaska cases in 2014-2018, including the outbreak in 2018.

The pattern of disease in HiA is similar to that seen in *Haemophilus influenzae* type B (HiB) meningitis. In HiB meningitis, dexamethasone has been shown to decrease the incidence of severe hearing loss. In Alaska, there have been multiple cases of sensorineural hearing loss associated with HiA meningitis. It is suspected that dexamethasone may confer similar benefits in HiA meningitis. As a result, our local experts (including infectious disease and endocrinology experts) recommend giving dexamethasone with all cases of suspected bacterial meningitis.

Dexamethasone

• Indications: A child >6 weeks old with clinical meningitis or visibly purulent spinal fluid.

<u>Timing</u>: First dose should be given 10-20 minutes prior to or concurrent with the first dose of antibiotics; if given after antibiotics have been given, there is no evidence that dexamethasone will improve outcomes.
 <u>Dose</u>: Dexamethasone 0.15 mg/kg/dose IV.

• Course: If dexamethasone is initiated and HiA/HiB is confirmed, continue dexamethasone 0.15 mg/kg/dose IV Q6h for 2-4 days. If CSF culture/PCR show a different pathogen or are negative, stop the dexamethasone.

Hearing Screening

All children with bacterial meningitis should be referred to audiology.
Hearing evaluation should be scheduled one month after hospital discharge.

168

This resource is designed for the general use of most patients but may need to be a dapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 4/6/21. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.





Pediatric Diabetic Ketoacidosis Management Protocol

General Guidelines and Definitions

Disclaimer: These are guidelines—not hard and fast rules. Some patients, such as younger children (<5 years) and poorly controlled diabetics (HbA1c >10%), may not adhere to the usual course and guidelines may need to be modified. The below categorizations of mild, moderate, and severe are not the consensus-statement published definitions, but are more "real-world" categorizations.

DKA: A state of *insulin deficiency* and characterized by severe depletion of water and electrolytes (see Appendix 1). The primary goals are to **treat the insulin deficiency** (which will correct the acidosis and reverse the ketosis) and to **replace fluids and electrolytes**. Other goals include gradually achieving euglycemia, monitoring for complications of DKA, and identifying and treating any precipitating event.

Clinical signs of DKA: dehydration, tachycardia, tachypnea, Kussmaul respirations, acetone breath odor, nausea, vomiting, abdominal pain, blurry vision, confusion, drowsiness, progressive decrease in level of consciousness, loss of consciousness.

Biochemical criteria for DKA: hyperglycemia (BG > 200 mg/dl); venous PH <7.3 or serum bicarb <15, beta-hydroxybutyrate ≥3 or moderate/large ketonuria

Diabetic ketosis without significant acidosis: Urine ketones moderate/large, nausea +/- vomiting, pH >7.3, Bicarb >15

- Management:
- Oral or IV hydration, depending on vomiting, ability to tolerate PO.
- Supplemental insulin (Novolog, SQ: 0.1-0.2 units/kg every 4 hours) in addition to patient's usual long-acting insulin (ie Lantus, Tresiba).
- Often managed as outpatient at home or in Emergency Department.

• In established patient with good family support, sometimes managed at home by phone under guidance from on-call physician with no knowledge of laboratory results other than self-monitored blood glucose and urinary ketones.

Mild-moderate DKA: Urine ketones mod/large, persistent vomiting, pH 7.2-7.3, Bicarb 10-15

Management:

• Oral or IV hydration (usually IV).

• Supplemental insulin should be used (Novolog SQ 10% of total daily insulin dose or 0.1-0.2 units/kg every 2 hours) in addition to the patient's usual long-acting insulin (ie Lantus, Tresiba).

May require admission and management with IV regular insulin infusion (0.05-0.1 units/kg/hr).

Severe DKA: Urine Ketones Large, pH <7.2, Bicarb <10 OR mild/moderate DKA with other organ system impairment (altered mental status, impaired renal function, respiratory distress, compromised circulation) (published definition: pH <7.1, bicarb <5) Management:

Admit to hospital for therapy and intensive monitoring.

• PICU status may be appropriate in some cases (altered mental status, hypokalemia, hyponatremia (after sodium corrected for glucose[†]), young age (<5 years),

hypotension, per admitting physician).

- IV hydration (3 L/m²/day)*
- IV insulin (0.1 units/kg/hour).
- Intensive monitoring for improvement and signs of cerebral injury.
- Follow guidelines as given in the remainder of this protocol.

Some useful formulas:

Total daily insulin dose approx. = Lantus dose x 2 (In general, Lantus dose is 50% of patient's total daily insulin)

[†]Corrected sodium = [((Glucose -100)/100) x 1.6] + Pt's Na [glucose is mg/dL]

^{*}BSA (m²)= sq root [(wt(kg) x ht(cm))/3600]; estimated BSA = (wt(kg) x 4 + 7)/(90 + wt(kg))

[‡]Anion Gap = Na – (CI + HCO₃); normal is 12 +/- 2 mmol/L

[€]Effective osmolality = 2 x (Na + K) + glucose/18 [glucose is mg/dl]

Fluid Management (2 bag system)

- Total fluids should not exceed about 3500 mL/m²/day.
- Volume expansion (fluid bolus) should be initiated prior to insulin administration, and insulin should be initiated at least 1 hour after the fluid administration has begun. • Initial bolus of NS or LR with 20 mL/kg over 1-2 hours.
- If poor peripheral perfusion, hypotension, or shock persist after the initial 20ml/kg, it may be appropriate to repeat with a second 10-20 mL/kg NS
 Rehydration: assume 10% dehydration and plan to replace the deficit over 24 hours. (See Appendix 2.)
 - This can often be accomplished by running IV fluids at 1.5 x maintenance or 3000 mL/m²/day.
 - Initial IVF with ½NS + 20 mEq/L K-phosphate + 20 mEq/L K-acetate (or KCl if K-acetate is not available). **Note: there is zero dextrose in this fluid.
 - Consider NS if measured Na level is low and does not rise with the fall in glucose.
 - If K is >6, repeat the BMP and add the K to the fluids when the K is <6; If K is low, may need up to 60 mEq/L K total (typically 30 and 30 of the two types of K solution).

• "Y-in" D10 ½NS + 20 mEq/L K-phosphate + 20 mEq/L K-acetate (or KCl) when the serum glucose is less than 250 mg/dL or if glucose falls faster than 100 mg/dL per hour.

• 2 bag method: Use 2 separate bags of IV rehydration fluid with identical electrolyte composition; one bag has NO dextrose and the other has 10% dextrose. Increase and decrease the rate of each bag reciprocally so that the total rate is constant at the desired rehydration rate (ie, 3 L/m²/day) and the glucose is maintained between 150 and 250.

◆ Typically, when the BG is ≤ 250, run the 2 fluids at 50/50 rates and when the BG is <200, stop running the fluid without the dextrose and run the D10 fluid at 100% of the desired rate.

DO NOT REDUCE INSULIN INFUSION RATE BECAUSE OF FALLING BLOOD GLUCOSE UNTIL THE REDUCTION IS INDICATED.
 BASED ON RESOLUTION OF KETOACIDOSIS; If the patient is still acidotic, they still need the insulin—increase the dextrose content

instead (can use D12.5% fluids prn).

• Do not administer sodium bicarbonate to correct the acidosis (cautious administration may be considered if pH <6.9 and the acidosis is so profound as to adversely affect the action of epinephrine during resuscitation, decreased cardiac contractility, impaired tissue perfusion from vasodilation, or life-threatening hyperkalemia; dose should be 1-2 mmol/kg over 60 minutes).

This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. If comments about this protocol, please contact Jane_McClure@ykhc.org. Return to Table of Contents



Yukon-Kuskokwim HEALTH CORPORATION

Pediatric Diabetic Ketoacidosis Management Protocol

Insulin Therapy

• "Low-dose continuous IV insulin infusion" = 0.1 units/kg/ hour regular insulin, IV (conc. 1 unit/mL).

Start insulin 1 hour after initial fluids have been started but do not further delay in starting insulin.

• Do not give intravenous insulin bolus or subcutaneous insulin bolus when starting the continuous infusion. (*If a delay in starting the insulin infusion is expected to be longer than 1 hour (i.e. more than 2 hours after IVF have been started, then a SQ insulin dose may be warranted.)

• CONTINUE IV INSULIN INFUSION AT 0.1 UNITS/KG/HOUR UNTIL THE KETOACIDOSIS IS RESOLVED, bicarb >18, the anion gap is closed (AG <12)[‡], and the patient is awake and can tolerate PO fluids.

A lower continuous rate (0.05 – 0.08 units/kg/hr may be needed in patients with marked insulin sensitivity.

• Usually, long-acting basal insulin (ie Lantus, Tresiba) should be given at the usual time, even if the patient is on an insulin infusion (this is most frequently given at bedtime; its onset of action is approx. 1-2 hours).

 Administering basal insulin while on the insulin infusion allows us to d/c the insulin infusion when it is appropriate (see above) without waiting for subcutaneous insulin to be given; it also provides background insulin so that DKA does not recur after the insulin infusion is discontinued (remember: without SQ insulin, once the IV insulin infusion is stopped, the patient has no other insulin on board!)

• In new-onset diabetes, the usual starting total daily dose of insulin is 0.5-1 units/kg/day, 50% of which should be given as basal insulin; in known diabetes, the patient's home dose of basal can be used.

• For those patients on insulin pumps, they will not be on a long-acting basal insulin, so do not need to receive this unless there is a plan to not restart the patient's pump while they are hospitalized. Otherwise, they can simply be restarted on their pump when the IV insulin infusion is completed.

Cerebral Injury in DKA

The most common cause of death during DKA in children is clinically apparent cerebral injury, which occurs in about 0.5-0.9% of cases and manifests as sudden neurologic decline. It often occurs early in the course of DKA (sometimes even before treatment has been started) and when it is clinically apparent, the prognosis is usually poor; mortality rate is up to 21-24%. The pathogenesis is incompletely understood, but may result from cerebral hypoperfusion and the effects of reperfusion, along with neuroinflammation. Cerebral *edema* is likely a consequence (rather than the cause) of cerebral injury, and often develops hours or days after the diagnosis of brain injury.

Risk factors include:

- " Younger age; New-onset diabetes; Longer duration of symptoms
- · Sodium bicarbonate treatment for correction of acidosis
- · Administration of insulin in the first hour of fluid treatment
- Increased BUN at presentation
- · Greater hypocapnia at presentation after adjusting for degree of acidosis
- More severe acidosis at presentation
- An attenuated rise in measured serum sodium concentrations during therapy
- · Children with DKA are frequently sleepy, but warning signs and symptoms of cerebral injury include:
 - Worsening of Glasgow Coma Scale (GCS) Score
 - Slowing of heart rate, rising blood pressure, decreased O2 saturation (Cushing's Triad)
 - · Change in neurological status (restlessness, irritability, increased drowsiness, incontinence)
 - · Headache, vomiting, focal neurological signs, dilated/unresponsive/sluggish/unequal pupils, papilledema
 - · Decreasing urine output without clinical improvement or tapering of fluids

• CEREBRAL INJURY IS A LIFE THREATENING MEDICAL EMERGENCY REQUIRING IMMEDIATE AGGRESSIVE INTERVENTION AND IMMEDIATE TRANSFER TO AN INTENSIVE CARE UNIT SETTING.

- Treatment includes:
 - . Give Mannitol 0.5-1 gm/kg over 10-15 min and repeat if no initial response in 30 minutes to 2 hours.
 - ♦ Hypertonic saline (3% saline) 2.5-5ml/kg over 30 min may be an alternative or 2nd line.
 - Elevate the head of the bed to 30 degrees and keep the head in a midline position.
 - Adjust fluid administration as indicated to maintain normal BP and optimize cerebral perfusion; avoid hypotension that might compromise cerebral

perfusion pressure.

• Administer oxygen as needed to maintain normal oxygen saturation.

• Intubation may be necessary if impending respiratory failure, but aggressive hyperventilation to hypocarbia (pCO₂ <22 mmHg) has been associated with poor outcome and is not recommended.

• Head CT scan should be obtained to rule out other possible intracerebral causes of neurologic deterioration AFTER treatment for cerebral injury has been started (DO NOT DELAY TREATMENT TO GET THE HEAD CT!); changes that will be detectable on head CT often occur late in the development of cerebral injury.

Monitoring and Other Recommendations

- Height and weight are both needed in order to calculate body surface area.
- Vital Signs Q1 hour for at least first 12 hours, then Q2 hours; HR monitor and pulse oximetry.
- Neuro checks/GCS score Q1 hour.
- Strict monitoring of Intake and Output is essential (Strict I/O).
- Check blood sugar (bedside glucose) every hour while on insulin infusion.

• NPO until acidosis is resolved in order to strictly monitor total intake, avoid excessive fluid administration, and decrease the risk of aspiration should consciousness be altered.

- BMP, Magnesium, Phosphorus, beta-hydroxybutyrate initially and q4-6 hours.
- I-Stat-7 Q2 hours until pH >7.25, then q4-6 hours.
- After first 12-18 hrs of DKA treatment, check urine ketones every void until negative twice in a row.
- Mannitol 1 gm/kg or 3% Saline at bedside (and ready to be given for acute change in mental status).
- Two peripheral IV catheters should be placed for fluid and insulin administration and for blood sampling.
- A flow sheet with lab results and clinical response can be a useful guide to therapy.

• Initial labs should include: Hemoglobin A1c, BMP, Mg, Phos, Beta-hydroxybutyrate, diabetes autoantibodies (islet cell antibody, insulin antibody, glutamic acid

decarboxylase (GAD-65) antibody, ZnT8 antibody), celiac panel (total IgA and TTG), TSH and free T4 (if patient is very ill, the TSH and free T4 should wait until child is more stable to avoid abnormalities of "sick euthyroid syndrome"), insulin and c-peptide (do not measure insulin if patient has already been started on insulin), CBC, cultures if indicated (fever, etc; **leukocytosis is a common finding in DKA and does not alone indicate infection).

• Call 907-563-2662, ask to speak with pediatric endocrinologist on call any time of the day or night.

This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. If comments about this protocol, please contact Jane_McClure@ykhc.org.



С

Yukon-Kuskokwim HEALTH CORPORATION

Treatment Protocol

Pediatric Diabetic Ketoacidosis Management Protocol

Prevention of DKA is key

• In patients with newly diagnosed diabetes, education of the public and health care providers to recognize early signs of diabetes can lead to diagnosis of type 1 diabetes before DKA develops.

• In patients with known diabetes, sick day reeducation with diabetes educator is important to discuss factors that led to DKA in this situation and how to avoid it in the future (ie urine ketone monitoring with illness or high blood glucose, avoiding insulin omission, appropriate use of insulin pump and trouble-shooting with pump problems).

Appropriately manage sick days and ketones at home or in the hospital to prevent progression to DKA (see below).

Sick day management guide when a patient has ketones based on amount of ketones and the blood sugar							
Urine Ketones	les Blood Glucose						
	<100	100-200	Over 200				
Neg/Trace/Small	Push sugar-containing fluids	Push fluids (sugar and sugar-free)	Push sugar free fluids; continue to check ketones while ill; give correction dose if BG>250-300				
Moderate	Push ~30-60g carBG to get BG over 200, consider mini-dose glucagon (see below)	Push ~30g carbs to get BG over 200 (recheck BG q 30-60min)	Give extra NovoLog (10% of total daily dose or 0.1 units/kg or double the BG correction dose); check BG and ketones in 2 hrs; repeat Novolog dose in 2 hrs if ketones do not decrease				
Large, but well patient (not continuously vomit- ing, no difficulty breath- ing, awake)	Push fluids (30-60g carBG), con- sider mini-dose glucagon	Push ~30 g carbs to get BG over 180-200 (recheck BG q30-60 min)	Give extra Novolog (20% of total daily insulin dose or double the BG correction); check BG and ket in 2 hrs ; repeat Novo- Log dose in 2 hours if ketones do not decrease				
Large, and sick pt (cont vomiting, difficulty breath- ing, lethargy)	Bring to ER, consider mini-dose glucagon on the way	Bring to ER Cont to push fluids if possible on the way	Bring to ER (can give an extra insulin dose while on their way to the ER if they live far away)				

Total daily insulin dose approx. = 2 x Lantus/Tresiba dose

Double the correction: calculate what insulin dose would be based on their BG correction factor and give 2 x that dose

References:

Kuppermann et al, N Engl J Med. 2018: 378(24):2275-87 Woflsdorf et al, Ped Diab. 2018:19 (Suppl 27):155-77 Wolfsdorf et al, Diab Care. 2006:29(5):1150-59

White NH, Washington Univ in St Louis; 1989 (rev 2003)




FIGURE 1	Pathophysiology of diabetic ketoacidosis. Copyright© 2006 American Diabetes Association. From diabetes care, Vol.
29, 2006:1	150-1159. Reprinted with permission of The American Diabetes Association

Appendix 2: Fluid maintenance and replacement volumes based on body weight and an assumption of 10% dehydration

Body weight Maintenance		DKA: give mai +5% of body v	
(kg)	(mL/24 h)	mL/24 h	mL/h
4	325	530	22
5	405	650	27
6	485	790	33
7	570	920	38
8	640	1040	43
9	710	1160	48
10	780	1280	53
11	840	1390	58
12	890	1490	62
13	940	1590	66
14	990	1690	70
15	1030	1780	74
16	1070	1870	78
17	1120	1970	82
18	1150	2050	85
19	1190	2140	89
20	1230	2230	93
22	1300	2400	100
24	1360	2560	107
26	1430	2730	114
28	1490	2890	120
30	1560	3060	128
32	1620	3220	134
34	1680	3360	140
36	1730	3460	144
38	1790	3580	149
40	1850	3700	154
45	1980	3960	165
50	2100	4200	175
55	2210	4420	184
60	2320	4640	193
65	2410	4820	201
70	2500	5000	208
75	2590	5180	216
80	2690	5380	224



Pediatric Endocrine Emergency Protocols

Hypoglycemia

If low BG and cause unknown, GET CRITICAL SAMPLE PRIOR TO TREATMENT!

Labs tested during hypoglycemia are critical to identifying cause and preventing recurrence.

- · Serum critical sample:
 - BMP, insulin, C-peptide, Cortisol, GH
 - Free fatty acids, β-hydoxybutyrate, acetoacetate
 - Lactate, ammonia, Save serum (sulfonylureas), total and free carnitine
- At any time:
- Acylcarnitine profile, serum amino acids
- Urine as quickly after hypoglycemia as possible
 - Urine ketones
- Urine organic acids

• If suspect hyperinsulinism, perform glucagon stim test (administer 0.03 mg/kg, max 1 mg) and measure lab glucose at 0, 15, and 30 minutes.

Acute Treatment: obtain critical sample and correct hypoglycemia within 10-15 minutes.

Glucose gel per eCHAM guidelines.

- IV or IO dextrose bolus (D10% or D25%) followed by continuous infusion of dextrose IVF and frequent blood sugar checks (Q1-2h or more frequently initially)

 D25%: 2-4 mL/kg; D10%: 5-10 mL/kg. (For neonates, give D10% 2 mL/kg.)
- If insulin-mediated, treat with glucagon 0.03 mg/kg up to 1 mg OR for patients < 20 kg give 0.5 mg IM and for patients > 20 kg give 1 mg IM.

Adrenal Insufficiency

Critical Sample before treatment: cortisol

- If suspect primary adrenal insufficiency, include ACTH, renin, aldosterone.
- If suspect CAH, include 17OH-progesterone or CAH-6b panel (send-outs).
- Also check BMP, CBC, U/A.

Treat while awaiting results.

Normal Saline Bolus 20 mL/kg.

- Hydrocortisone 50-100 mg/m² IV bolus (lower end of range if less sick, higher end of range if more sick) followed by 50-65 mg/m²/day, divided q6h
 - . If no IV access, SoluCortef IM or Dexamethasone IM
 - SoluCortef 50-65 mg/m² IV/IM short acting
 - At this dose, adequate mineralocorticoid activity to replace moderate doses of oral fludrocortisone (80 mg HC = 0.2 mg fludrocortisone)
 - Dexamethasone 1.5-2 mg/m² IV/IM—long acting
 - No mineralocorticoid activity
 - Does not cross react with cortisol in lab assay so can use Dex if unable to get cortisol before treatment and then do Cortrosyn stimulation

test after treatment

SoluMedrol 10-15 mg/m² IV/IM–intermediate acting

No mineralocorticoid activity

• For milder presentation, ex. known diagnosis with flu symptoms, but hemodynamically stable, can skip load, use 50-65/m²/day, divided every 6 hours.

Known adrenal insufficiency (ie CAH or hypopituitarism) and adrenal crisis

• Loading dose hydrocortisone IV or IM 50 mg/m² x1 then 50 mg/m²/day divided q6h

• If BSA unknown or for more rapid dosing, can use age:

<3 y.o.: 25 mg IM/IV bolus followed by 25-30mg/day divided q6h

3-12 y.o.: 50 mg IM/IV bolus followed by 50-60mg/day divided q6h

>12 y.o.: 100 mg IM/IV bolus followed by 100mg/day divided q6h

• If severely ill or unable to take PO due to continued emesis, but no IV, can give SoluCortef 30-50 mg/m² IM (better for CAH because has fludrocortisone activity at high doses, but only lasts about 6 hours), or Dexamethasone 1.5-2 mg/m² IM.

• If less ill (ie, not in crisis but needs stress doses because of fever or vomiting), can give double or triple oral dose (usually double if fever, triple if vomiting or more sick).

• Normal saline bolus 20 mL/kg/ IV then D5NS or D10NS (depending on blood sugar) at 1.5 x maintenance.

• Monitor electrolytes, BP.

• For anesthesia: begin triple dose the night before the procedure, then 30-50 mg/m² IV or IM on call to the OR prior to anesthesia; and continue stress doing for 24 hours after procedure.





Pediatric Endocrine Emergency Protocols

Hypercalcemia

Critical sample: Ca, Phos, iPTH

- Other labs: 25-OH-D, 1,25 (OH)₂ D, urine Ca/Cr, CBC
- Treatment for severe hypercalcemia (Ca >14): same initial treatment independent of the cause
- Saline diuresis: NS bolus followed by 2.5-3 L/m²/day
- Saline diuresis generally works rapidly, but only as long at it is continued, and usually does not normalize calcium.
- Consider calcitonin 4 units/kg IV/IM/SQ q12h
 - Tachyphylaxis common (often 2nd-line therapy y
 Common side effects: nausea, vomiting, flushing
- May need bisphosphonates.
- Discontinue any medications known to cause or worsen hypercalcemia.
- Avoid immobilization.

If mild/moderate (Ca <13-14) and no contraindication to PO: 2-3 L/day water plus PO salt to promote Ca excretion.

Therapy specific for underlying disorder

- Hyperparathyroidism → parathyroidectomy
- Glucocorticoids → effective if associated with hematologic malignancy or diseases with increased 1,25 (OH)₂ vitamin D.

Hypocalcemia

Critical sample: Calcium, Phosphorus, Magnesium, intact PTH before treatment.

- Ca and PTH need to be simultaneous, and PTH MUST be obtained while Ca is low.
- · Collect urine Ca/Cr while Ca low if possible.
- If there is reason to suspect low albumin, check ionized calcium or calculate corrected calcium using albumin
- Corr Ca = measured calcium + [0.8 (4-albumin)]
- Other useful labs: CMP (kidney, liver, bone function), 25-OH-D, 1,25 (OH)₂ D, urine Ca/Cr.

Treatment if Symptomatic - tetany, seizure, apnea, heart failure, laryngospasm.

- Slow (<1 ml/min) IV infusion 10% Ca gluconate 1 mL/kg
 - 100 mg/ml Ca Gluconate = 9 mg/mL elemental Ca
 - Cardiac monitoring (bradycardia, shortened QT_c); close attention to infusion site if not central IV (risk of tissue necrosis if peripheral IV infiltration)
- If Mg low, replace with 0.1-0.2 mL/kg 50% Mg Sulfate

If not acutely symptomatic, can do more comprehensive evaluation first to determine cause and appropriate oral treatment.

This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. If comments about this protocol, please contact Jane_McClure@ykhc.org.



Thyroid Storm (Thyrotoxic Crisis)

Score \geq 45 \rightarrow highly suggestive of thyroid storm; 25–44 \rightarrow thyroid storm; and <25 \rightarrow thyroid storm unlikely.

Thermoregulatory dysfunction	Score
Temperature (C)	
37-37.7	5
37.7-38.3	10
38.3-38.8	15
38.8-39.3	20
39.4-39.9	25
40	30
Central nervous system effects	
Mild - agitation	10
	10
Moderate - delirium, psychosis, extreme lethargy	20
Severe - seizure, coma	30
Gastrointestinal-hepatic dysfunction	
Moderate - diarrhea, nausea/vomiting, abdominal pain	10
Severe - unexplained jaundice	20
Cardiovascular dysfunction	
Tachycardia (heart rate/min)	
99-109	5
110-119	10
120-129	15
130-139	20
≥ 140	25
Congestive heart failure	
Mild - pedal edema	5
Moderate - bibasilar rales	10
Severe - pulmonary edema	15
Atrial fibrillation	10
Precipitant history	
Negative	0
Positive	10

Pediatric Endocrine Emergency Protocols

Critical Sample: Free T4 and TSH, run STAT

- Other labs: TBII, TSI, TPO antibodies
- Useful to measure: CMP (glucose, liver function), CBC (acute infection?), urine pregnancy test

Acute Treatment

- Oxygen
- Adrenergic blockade (if not in CHF) goal HR<100

 $_{\circ}$ Propranolol (PO 2 mg/kg/day div q6-8h or IV 0.01 mg/kg/dose (max 5mg) over 10-15 min).

 If contraindication to propranolol (ie asthma), can use atenolol (cardioselective) with caution.

- IV fluids (cooled if necessary)
- Cooling blankets
- Antipyretics should be avoided when possible.
- Sedation phenobarbital stimulated thyroid hormone clearance.
- · Hemodynamic support/treat CHF if present.

Longer term treatment:

- Block thyroid hormone synthesis and release
 - Thionamides block thyroid hormone synthesis
 - PTU (propylthiouracil): black box warning in peds
 - Methimazole : ~0.8 mg/kg up to 60 mg loading, then ~0.4 mg/kg up to 30 mg every 6 hours (5, 10 mg tabs)
 - High Dose Iodine blocks release of already formed thyroid hormone
 - Should be delayed until 1-2 hours after thionamide, to prevent transient increase in thyroid hormone levels
 - SSKI (Lugol solution) 5 drops every 6-12 hours
 - Use will necessitate delay in radioactive iodine
 - treatment if that is desired
- Block peripheral conversion of T4 to T3
 ^a Corticosteroids (stress dose HC or equivalent)
 - Propranolol

 - Iodinated contrast agents

Identify and treat precipitating event causing severe decompensation. • Infection, pregnancy, emotional stress, DKA, pulmonary embolism, CVA, trauma, hypoglycemia.

Assess for underlying cause

· Grave's disease, functioning thyroid nodule ("hot nodule").

174

This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. If comments about this protocol, please contact Jane_McClure@ykhc.org.



Pediatric Endocrine Non-emergency Recommendations

Please remember that this is just a list of lab tests often recommend prior to seeing patients. These are not physician orders. However, they are recommended prior to specialty appointments.

Congenital Adrenal Hyperplasia (CAH): meds are often adjusted based on labs/growth/bone age

- 17-OH-P (17-OH hydroxyprogesterone) often every 3-6 months Infants/toddlers often ordered q 1-3 months. (Goal: ~300-900)
- Androstenedione: Often every 3-6 months. Infants/toddlers often ordered every 1-3 months. (Goal: w/in normal range)
- Renin Activity: Often every 3-6 months. Renin hard to obtain in villages as must be sent frozen. (Goal: w/in normal range)
- · Bone age after 2-3 years of age, then annually
- Accurate height and weight measurements each visit
- F/u in endo clinic every 3 to 6 months

Newborn with + FH of CAH but no ambiguous genitalia (ie no physical s/s of CAH):

Newborn screen after 24hrs of life (in all infants).

• Serum 17OHP around day 3-4 of life (17OHP levels are normally high during the first 2-3 days after birth but by the 3rd day, levels in healthy infants fall and levels in affected infants rise to diagnostic levels).

· Alert state newborn screening program of patient at risk of CAH.

• Measure serum electrolytes prior to hospital discharge and at 5 and 10 days of age (hyponatremia and hyperkalemia are usually not present before 7 days of age and salt-losing crisis will typically occur in the second week of life).

• After newborn is sent home, parents should be cautioned to watch for signs of salt-losing crisis including vomiting, diarrhea, lethargy, dehydration, decreased PO intake.

• If positive newborn screen or elevated 17OHP, patient should be seen immediately and consult endocrinologist on call.

Congenital Hypothyroid/Hashimoto Thyroiditis/Goiter: meds are usually adjusted based on labs

General Information

- When a med dosage change is made, labs are usually repeated in 4-6 weeks and then again before the next clinic visit.
- Under certain circumstances, a thyroid ultrasound is sometimes ordered not routine.
- · Growth records on all children with any thyroid condition should be plotted.
- Often other thyroid labs are done as part of initial workup, but depends on what the presumptive diagnosis is. (TSI, Antithyroid peroxidase AB, etc.)

Specific Labs - Goal: normal Free T4 and TSH (infants should have a free T4 at least once).

Congenital Hypothyroidism

- FT4 & TSH 2weeks after dose started.
- 0-6 Months: FT4 & TSH every month
- 6-12 Months: FT4 & TSH every 2 months
- 1-3 Years: FT4 & TSH every 3 months

Acquired Hypothyroidism

- FT4 & TSH 4-6 weeks after starting med or after dose change
- FT4 & TSH every 6 months routinely

Central Hypothyroidism (ie, hypopituitarism)

• Free T4 every 4-6 months routinely

Hypopituitarism/Septooptic dysplasia/Optic nerve hypoplasia: (any combination of deficiencies of GH, TSH, ACTH, LH/FSH, ADH)

- Labs to follow depend on deficiency
- If panhypopituitarism
 - IGF-1 every 6-12 months if on GH (see below).
 - Free T4 every 4-6 months (see above).
 - May check BMP if concerns about inadequate adrenal hormone replacement.
 - Na levels if DI depend on thirst—if intact thirst, Na level every 3-4 months; if non-intact thirst, may need Na every 2-4 weeks.
 - LH/FSH pediatric, estradiol ultrasensitive or total testosterone at approximately age 12.
 - Accurate height and weight plotted on growth chart.

Work-up of Short Stature

- · X-ray: bone age XR left hand/wrist
- bloodwork: TSH, free T4, TTG IgA, IgA, CMP, CBC, IGF-1, IGFBP-3, ESR. Also do chromosome microarray if a girl.
- urine: urinalysis (looking for RTA)

This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. If comments about this protocol, please contact Jane_McClure@ykhc.org.





Treatment Protocol

Pediatric Endocrine Non-emergency Recommendations

Children on Growth Hormone Injections: (GH deficiency/Turners/Noonan's/Prader-Willi Syn/SGA/Panhypopituitarism/CRF)

Free T4 and IGF-1

- Usually obtained q 6-12 months. Other labs including these may be done for initial diagnosis which may include GH stimulation tests.
- GH dose will be adjusted based on IGF-1, growth pattern and weight.
- Bone age: includes left hand and wrist please have radiology send via PACS to ANMC.
- Initially and approximately every year.
- Accurate height and weight

• Crucial to have correct plotting on growth record. (Lengths are done on infants and toddlers less than 2 years of age or if not able to stand well; plotted on 0-24mo WHO growth chart; heights are done when the child is over age 2 and plotted on the CDC 2-20 growth chart.)

Insulin Resistance/Obesity: goal is to prevent these children from becoming diabetic; not usually managed in endocrine clinic unless there is an endocrine condition (diabetes, prediabetes, PCOS, dyslipidemia); hypertension is managed by PCP or nephrology. ** Refer to publications in *Pediatrics*.

- Screening fasting plasma glucose, HbA1c every 2 yrs. OGTT if needed (Fasting Insulin not routine).
 - Fasting plasma glucose <100 is normal; 100-125 = prediabetes, >125 = diabetes.
 - OGTT-fasting plasma glucose, then drink 1.75 g/kg (max 75 g) of Glucola (within 10-15 min) and repeat plasma glucose in 2 hours.
 - ◆ Fasting 101-125 = impaired fasting glucose; over 125 = diabetes
 - ◆ 2 hour 141-199 = impaired glucose tolerance; over 199 = diabetes
 - HbA1c: 5.7% to 6.4% = prediabetes; >6.4%, likely diabetes but not necessarily diagnostic in children
- Fasting lipids initially and then per recommendation, usually every 2 years
 - If abnormal, repeat after 2 weeks but before 3 months (see below).
 - If still abnormal, dietitian referral.
- · Liver function tests-AST/ALT every 2 years.
- · Growth records with accurate height & weight plotted-also calculate and plot BMI.
- Only obtain TSH & Free T4 initially if patient is showing growth deceleration.
- All patients should have initial evaluation and then monthly appointments with a dietitian whenever possible.
 - Daily activity, one hour/day with lifestyle change.
 - The more they see their primary provider and dietician, the more likely they are to comply with changes in dietary and activity levels.

Type 2 Diabetes

• At diagnosis: HgbA1C. Other labs depend on the individual case.

- Criteria for dx of diabetes (per ADA):
 - FPG > 125 (no caloric intake for 8 hrs)
 - OR 2-hr glucose >199 during an OGTT
 - OR HbA1c >6.4% (**controversial for dx in children)
 - **the above 3 criteria require repeat testing in the absence of unequivocal hyperglycemia)
 - OR classic symptoms of hyperglycemia or hyperglycemic crisis and a random plasma glucose >199
- HbA1c every 3 months: Goal A1c <7%
- Fasting lipid panel soon after diagnosis and every 5 years if normal.
 - If abnormal, repeat after 2 weeks but before 3 months (see below).
 - If still abnormal, dietitian referral.
- Random urine microalbumin/creatinine soon after diagnosis and annually.
 - If abnormal, repeat with first morning urine MA/Cr or overnight collection; if still abnormal, referral to nephrology.
- Eye exam soon after diagnosis and annually.
- · Dental exam annually.
- Dietician visit q 3-6 months.
- RN-CDE for education.





Type I Diabetes Mellitus

New Diagnosis: HbA1c, BMP, c-peptide, insulin level, other labs depending on patient and presentation (for diagnostic criteria, see above; type 1 distinguished from type 2 based on presentation, physical exam, sometimes on labs such as c-peptide and diabetes antibodies)

- · Hemoglobin A1C: Every 3 months (lifetime standard of care for DM)
 - This lab helps determine the overall status of blood glucose readings over a 3 month period and gives an average of all readings.
 - A1c goal is generally 7%; infants and toddlers, tolerate A1c goal of ~8%.
- Fasting Lipid Panel
 - ^a Initial check soon after diagnosis, once blood sugars stabilized, if over 2 years old.
 - Repeat fasting lipid panel every 5 years if initial is normal (starting at 9 years old).
 - If abnormal, fasting lipid panel should be repeated at least 2 weeks later but less than 3 months later to confirm.
 - If confirmed abnormal, referral to dietician for lifestyle/diet
 - modification.
- Thyroid and Thyroid Auto Antibodies
 - Obtain Free T4 & TSH at diagnosis and annually.
- Antibodies not routine, but if done it includes thyroid peroxidase AB.
 Celiac screening
 - TTG IgA and total serum IgA soon after diagnosis.
 - Annually for the first 5 years, more frequent if symptoms.
- Eye exam
 - Initial eye exam soon after diagnosis to detect cataracts or major refractive errors
 - Annual eye exam should start at:
 - 9 years if 5-year duration diabetes.
 - 11 years if 2-year duration diabetes.
 - After 2 years duration if diabetes diagnosed in an adolescent.
- Urine microalbumin/creatinine screen
 - Spot urine microalbumin/creatinine annually after age 10 years.
 - If abnormal, repeat with first morning void or an overnight urine
 - collection.
- Flu Vaccine recommended yearly.
- Dental evaluation recommended yearly.
- RN CDE referral for all aspects of Diabetes education. Work closely with CDE
- if patient is on Lantus + rapid acting insulin intensive regimen-ideally.
- Dietitian CDE for dietary/CHO counting/activity/insulin (learning to count carbs).
- All children should see Pediatric Endocrinologist every 3 months (may
- alternate depending on needs of family/primary provider).
 - Families need to know when to do Urine Ketones: if BS over 300 or if ill.

Pediatric Endocrine Non-emergency Recommendations

Table 9-1. Acceptable, Borderline-High, and High Plasma Lipid, Lipoprotein
and Apolipoprotein Concentrations (mg/dL) For Children and Adolescents*

Category	Acceptable	Borderline	High+
TC	< 170	170-199	<u>> 200</u>
LDL-C	< 110	110-129	<u>> 130</u>
Non-HDL-C	< 120	120-144	<u>> 145</u>
ApoB	< 90	90-109	≥ 110
TG			
0-9 years	<75	75-99	<u>> 100</u>
10-19 years	< 90	90-129	≥ 130
Calman		Constanting .	· · ····

Category	Acceptable	Borderline	Low	
HDL-C	> 45	40-45	< 40	
ApoA-I	>120	115-120	<115	


"Values for plasma lipid and lipoprolein levels are from the National Cholesterol Education Program (NCEP) Expert Panel on Cholesterol Levels in Children. Non-HDL-C values from the Bogaluss Heart Study are equivalent to the NCEP Pediatric Panel out points for LDL-C. Values for plasma spoß and spoA-I are from the National Health and Nutrition Exemination Survey II.

The cut points for high and borderline-high represent approximately the SSB and 75b percentiles, respectively. Low cut points for HOL-C and apoA-1 represent approximately the 10th percentile.

This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. If comments about this protocol, please contact Jane_McClure@ykhc.org.



Infant Hip Exam and Surveillance Protocol



Orthopedics Consults & Referrals

- 1. Consultation:
 - Beneficiary patients: contact ANMC orthopedic surgeon on call at (907) 563-2662 (*97) or send message through Tiger Connect.
 - Non-beneficiary patients: contact Ken Thomas, MD at Anchorage Fracture & Orthopedics at (907) 563-3145.
- 2. Referral:
 - Place an order for "Refer to Orthopedics External" with brief history. Note the orthopedist who was consulted. Indicate where the referral should be sent.
 - Send a RAVEN Communication to Chronic Peds Case Manager Pool about the referral and level of importance.

Imaging

Patient must have either ultrasound or X-ray, as below.

- 1. Hip ultrasound: 6 weeks to 4 months of age.
 - Performed at Alaska Regional Hospital.
 - Place order for "Refer to Pediatric Clinic External (MRI / EEG / VFSS / Hip US)" with brief history.
 - If patient is a beneficiary, request follow-up appointment at Southcentral Foundation Team B.
 - If patient is not a beneficiary, request follow-up appointment with a pediatric provider in Bethel.
 - Send a RAVEN Communication to Chronic Peds Case Manager Pool about the referral and level of importance.

2. <u>X-ray, AP pelvis</u>: over 4 months of age. (Note: in premature infants, ossification of femoral heads is delayed. May use corrected gestational age of 4 months or later.)

- Performed at YKHC.
- Place an order for "XR Pelvis (Pelvis AP only)" and put in comments "AP view with hips in neutral position to rule-out developmental dysplasia of the hip."
- Send a RAVEN Communication to Chronic Peds Case Manager Pool stating the order was placed and requesting an appointment for this with a pediatric provider in Bethel.

This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 12/2/20. Click here to see the supplemental resources for this guideline. If comments about this protocol, please contact Leslie_Herrmann@ykhc.org.



POLICY: To obtain sputum samples safely and effectively in pediatric patients

PROCEDURE: Induced Sputum Collection in Pediatric Patients

1. Premedicate with albuterol 2.5 mg/3mL (0.083%) solution – 3 mL via nebulizer to induce bronchodilation and better facilitate delivery of hypertonic saline. This can help prevent the development of bronchospasm during delivery of hypertonic saline. An MDI with a mask and spacer is an acceptable substitution.

2. Give 5 mL of 3% hypertonic saline solution via nebulizer over period of at least 10 minutes. Prolonged administration has been shown to yield better samples.

3. If patient has copious nasal secretions, consider nasal suction with olive tip.

4. Obtain mucus specimen trap with suction catheter appropriate for patient size. Measure from tip of nose to the tragus for depth of catheter insertion and obtain sample via suction of the nasopharynx. The goal is to induce a gag and then a cough. Sample is expected to be blood-tinged.

Note: This process may induce a vagal response. The patient should be sitting up with feet supported or lying down, NOT standing. If vasovagal syncope does occur, immediately place the patient supine with the legs elevated.

5. Place specimen in appropriate collection container for desired test. Precise labeling is essential to prevent specimen rejection from state lab.

a. For rule-out pulmonary tuberculosis, collect 3 induced sputum samples at least 8 hours apart – one must be first morning sample. Send for Acid Fast Bacilli Smear and Culture. Sample must be in an AFB container (conical with orange top), with a minimum volume of 5 mL; add sterile water to dilute if necessary. Two samples should also be sent for Xpert MTB-RIF. These samples should be 3-5 mL of mucous in a sterile specimen cup. Do not dilute, or "saline wash" nares during suction for this specimen. AFB and Xpert may be obtained at the same time; if quantity not sufficient for both tests, prioritize the AFB.

b. Standard sputum cultures do not have a minimum volume and can be placed in a sterile specimen cup.

c. Label must contain full user name of collector and date and time of the collection. This should be written below the barcode, NOT beside it.

d. Collect specimen in RAVEN. Confirm the correct accession number and deselect any additional (future) accession numbers. Ensure the collector ID, date, and time entered into RAVEN are an exact match to the written label.

*Contraindications to above procedure: oxygen saturation of <92% despite supplemental oxygen therapy, inability to protect the airway, severe bronchospasm, or designation as inappropriate by the clinician for another reason (eg., midface trauma). After exclusion or resolution of these conditions, sputum induction can be considered.


Note: This procedure can also be used for patients who are able to follow instructions but do not have a productive cough. In these cases, suction may or may not be necessary.

This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 12/2/20. Click here to see the supplemental resources for this resource. If comments about this protocol, please contact Amy_Carson-Strnad@ykhc.org.



Clinical Protocol

mPEWS Protocol for Pediatric Patients



This protocol is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 3/1/22.

If comments about this guideline, please contact Leslie_Herrmann@ykhc.org



Documentation Requirements for Pediatric Nutritional Supplements

Documentation Requirements for Pediatric Nutritional Supplements

The following resource is from the Medicaid Certificate of Medical Necessity.

Medicaid, Medicare, and other insurers have specific requirements for medical provider documentation. If those requirements are not met, nutritional supplements will not be covered.

Documentation Requirements for the Prescription of Nutritional Supplements:

The following objective documentation is required to show the medical necessity of the orthotic services being prescribed.

This information needs to appear in the body of the medical provider's chart notes:

- Diagnosis of the patient.
- Product being prescribed and why it is needed. (Example: Pediasure)
- · Goal or target weight for the patient.
- Total daily caloric requirement.
- Total daily calories obtained from ingestion (oral) foods.
- Total daily calories to be obtained from nutritional supplement.

Documentation Example

Pediasure is medically necessary for this child.

Diagnosis: dysphagia (R13.10), G-tube dependence

Product: Pediasure

Medical Necessity: Patient has severe dysphagia. He is undergoing oral feeding therapy but is unable to take any degree of sufficient calories by mouth and is thus entirely dependent on a G-tube for nutrition. Pedias ure will give him the nutrition he needs to survive.

Goal/target Weight: currently at target weight of XX kg (XXth percentile for age when corrected for prematurity). Target weight along this trajectory in one year will be XX kg.

Total Daily Caloric Requirement: XX calories/day (usually estimate 100-120 cal/kg/day - adjust based on growth)

Total Calories Obtained from Oral Intake: 0 calories/day

Total Daily Calories to be Obtained from Nutritional Supplement: XX calories/day

This resource is designed for the general use of most patients but may need to be a dapted to meet the special needs of a specific patient as determined by the medical practitioner. If comments about this resource, please contact Tamara_Hill@ykhc.org.



Orthotics, Documentation Requirements

Documentation Requirements for Pediatric Orthotics

The following resource is from Northern Orthopedics, Inc.

Medicaid, Medicare, and other insurers have specific requirements for medical provider documentation. If those requirements are not met, orthotic devices will not be covered.

Documentation Requirements for the Prescription of Orthotic Devices:

The following objective documentation is required to show the medical necessity of the orthotic services being prescribed.

This information needs to appear in the body of the medical provider's chart notes:

- · Diagnosis of the patient.
- Item being prescribed and why it is needed.
- How long the patient is expected to use the item.
- If this is to be custom or non-custom item. (When custom, please specify why a non-custom item will not work.)

If you are prescribing repairs/adjustments or a replacement to an existing orthosis:

- Document that the patient still requires a functioning orthosis.
- Explain why the current orthosis is no longer able to function as intended.

Please fax chart notes documenting this required information to Northern Orthopedics, Inc. Fax: (907) 561-2157.

If you have any questions about this required documentation feel free to call Northern Orthopedics, Inc. at (907) 561-1777.

This resource is designed for the general use of most patients but may need to be a dapted to meet the special needs of a specific patient as determined by the medical practitioner. If comments about this resource, please contact Tamara_Hill@ykhc.org.



n

Yukon-Kuskokwim HEALTH CORPORATION

Suspected Septic Arthritis & Osteomyelitis

Please see the <u>ANMC Pediatric Acute Hematogenous</u> <u>Septic Arthritis/Osteomyelitis Guideline</u>.

• Please note: this guideline was designed at ANMC, where recommended labs, MRI, and operative management are immediately available and antibiotics can be started after these interventions.

When evaluating a patient at YKHC with possible septic arthritis or osteomyelitis, strongly consider empiric antibiotics if there is going to be a delay of >6 hours to perform the recommended work-up (joint aspiration, surgical drainage, etc.), as noted in ANMCs guideline.
Always discuss antibiotics with ANMC consultants and advocate for empiric usage if appropriate. Keep in mind possible delays, including weather, transport difficulties, and other emergencies. If deferring antibiotics, ensure that patient is closely monitored for development of worsening infection.

Always feel free to consult YKHC pediatric hospitalist with any questions.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by MSEC 4/6/21. If comments about this guideline, please contact Leslie_Herrmann@ykhc.org.